[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 130
1. Seimiya YM, Takahashi M, Furukawa T, Mizutani K, Kimura K, Haritani M: An aged bull with concurrent thyroid C cell carcinoma, adrenal pheochromocytoma and pituitary chromophobe adenoma. J Vet Med Sci; 2009 Feb;71(2):225-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An aged bull with concurrent thyroid C cell carcinoma, adrenal pheochromocytoma and pituitary chromophobe adenoma.
  • Pathological examination disclosed multiple endocrine tumors including thyroid C cell carcinoma with metastases to the cervical lymph nodes and lung, adrenal pheochromocytoma and pituitary chromophobe adenoma in the pars distalis.


2. Brown RL, Muzzafar T, Wollman R, Weiss RE: A pituitary carcinoma secreting TSH and prolactin: a non-secreting adenoma gone awry. Eur J Endocrinol; 2006 May;154(5):639-43
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pituitary carcinoma secreting TSH and prolactin: a non-secreting adenoma gone awry.
  • To our knowledge, only one case of a TSH-secreting carcinoma has previously been reported.
  • We describe here a second patient with a pituitary carcinoma producing TSH and prolactin (PRL).
  • Pathologic examination revealed a chromophobe adenoma with increased mitotic forms.
  • The patient completed a course of external beam radiation to the pituitary and was prescribed l-thyroxine, bromocriptine, and hydrocortisone.
  • Emergent resection of the larger mass revealed a pituitary cancer with positive staining for PRL, but not for TSH.
  • Nine months later, the patient underwent further debulking of metastatic disease.
  • Although development of a carcinoma from a pituitary adenoma is very rare (<0.5%), macroadenomas that become hormonally active should be suspect for transformation into pituitary cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16645009.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK07011; United States / NCRR NIH HHS / RR / RR00055; United States / NCRR NIH HHS / RR / RR18372
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 9002-62-4 / Prolactin; 9002-71-5 / Thyrotropin
  •  go-up   go-down


3. Tan MH, Wong CF, Tan HL, Yang XJ, Ditlev J, Matsuda D, Khoo SK, Sugimura J, Fujioka T, Furge KA, Kort E, Giraud S, Ferlicot S, Vielh P, Amsellem-Ouazana D, Debré B, Flam T, Thiounn N, Zerbib M, Benoît G, Droupy S, Molinié V, Vieillefond A, Tan PH, Richard S, Teh BT: Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer; 2010;10:196
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma.
  • BACKGROUND: Chromophobe renal cell carcinoma (chRCC) and renal oncocytoma are two distinct but closely related entities with strong morphologic and genetic similarities.
  • Previous studies have been relatively limited in terms of examining the differences between oncocytoma and chromophobe RCC.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Biomarkers, Tumor / genetics. Carcinoma, Renal Cell / genetics. Chromosomes, Human, Pair 1. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genetic Testing / methods. Kidney Neoplasms / genetics. Polymorphism, Single Nucleotide


Advertisement
4. Mai KT, Dhamanaskar P, Belanger E, Stinson WA: Hybrid chromophobe renal cell neoplasm. Pathol Res Pract; 2005;201(5):385-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hybrid chromophobe renal cell neoplasm.
  • Hybrid renal cell neoplasms (HRCNs) containing areas of tumor cells displaying cytological features of chromophobe renal cell carcinoma (CHRCC) and renal oncocytoma (RO) have been recently described in patients with renal oncocytosis and Birt-Hogg-Dube (BHD) syndrome (autosomal dominant genodermatosis).
  • Chromophobe cells accounted for 20-80% of the tumors.
  • Hale's colloidal stain showed weak to moderate diffuse cytoplasmic staining in scattered cells corresponding to those displaying routine staining features of chromophobe cells.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16047948.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / KRT7 protein, human; 0 / Keratin-7; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


5. Geramizadeh B, Ravanshad M, Rahsaz M: Useful markers for differential diagnosis of oncocytoma, chromophobe renal cell carcinoma and conventional renal cell carcinoma. Indian J Pathol Microbiol; 2008 Apr-Jun;51(2):167-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Useful markers for differential diagnosis of oncocytoma, chromophobe renal cell carcinoma and conventional renal cell carcinoma.
  • Renal oncocytoma, conventional RCC (granular cell type) and chromophobe RCC have different prognosis.
  • In a 5-year study of 128 renal tumors, we selected 76 cases [30 conventional RCC (CRCC), 16 papillary RCC, 21 chromophobe RCC (ChRCC), 8 oncocytoma, 1 collecting duct carcinoma (cdc)] and staining with Hale's colloidal iron, CK7, CK8, CK18, CK19, CK20, Vimentin, EMA, CD10 and RCC marker were done.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis


6. Yamaguchi T, Kuroda N, Imamura Y, Hes O, Michal M, Sima R, Nakayama K, Sato N: Imprint cytologic features of chromophobe renal cell carcinoma morphologically resembling renal oncocytoma: is this an oncocytic variant of chromophobe renal cell carcinoma? Diagn Cytopathol; 2010 Jul;38(7):509-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imprint cytologic features of chromophobe renal cell carcinoma morphologically resembling renal oncocytoma: is this an oncocytic variant of chromophobe renal cell carcinoma?
  • In this article, we report a case of 76-year-old woman with a rare variant of chromophobe renal cell carcinoma (CRCC).
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Carcinoma, Renal Cell / pathology. Cytological Techniques / methods. Kidney / pathology. Kidney Neoplasms / pathology


7. Choi YD, Kim KS, Ryu S, Park Y, Cho NH, Rha SH, Jang JJ, Ro JY, Juhng SW, Choi C: Claudin-7 is highly expressed in chromophobe renal cell carcinoma and renal oncocytoma. J Korean Med Sci; 2007 Apr;22(2):305-10
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-7 is highly expressed in chromophobe renal cell carcinoma and renal oncocytoma.
  • We examined the immunohistochemical expression of claudin-7 and parvalbumin in 239 renal tumors, including 179 clear cell renal cell carcinoma (RCC)s, 29 papillary RCCs, 20 chromophobe RCCs, and 11 renal oncocytomas.
  • Claudin-7 and parvalbumin immunostains were positive in 3.4%, 7.8% of clear cell RCCs, 34.5%, 31.0% of papillary RCCs, 95.0%, 80.0% of chromophobe RCCs, and 72.7%, 81.8% of renal oncocytomas, respectively.
  • The sensitivity and specificity of claudin-7 in diagnosing chromophobe RCC among subtypes of RCC were 95.0% and 92.3%.
  • The expression pattern of claudin-7 was mostly diffuse in chromophobe RCC and was either focal or diffuse in oncocytoma.
  • Claudin-7 can be used as a useful diagnostic marker in diagnosing chromophobe RCC and oncocytoma.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / metabolism. Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / diagnosis. Kidney Neoplasms / metabolism. Membrane Proteins / metabolism

  • Genetic Alliance. consumer health - Chromophobe Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):203-10 [10680888.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):922-30 [9255255.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Aug;279(2):G250-4 [10915631.001]
  • [Cites] Mod Pathol. 2001 Aug;14(8):760-7 [11504835.001]
  • [Cites] Ann Diagn Pathol. 2002 Jun;6(3):154-8 [12089725.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):992-3 [9307205.001]
  • [Cites] J Pathol. 1997 Oct;183(2):131-3 [9390023.001]
  • [Cites] Am J Surg Pathol. 1998 Apr;22(4):419-24 [9537468.001]
  • [Cites] Mod Pathol. 1999 Mar;12(3):310-7 [10102617.001]
  • [Cites] Trends Cell Biol. 1999 Jul;9(7):268-73 [10370242.001]
  • [Cites] J Urol. 1999 Oct;162(4):1246-58 [10492174.001]
  • [Cites] Histopathology. 2004 Dec;45(6):593-602 [15569050.001]
  • [Cites] J Mol Diagn. 2005 May;7(2):206-18 [15858144.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):712-7 [12118108.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):199-205 [12548166.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):2021-33 [12673207.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):612-24 [12717246.001]
  • [Cites] J Membr Biol. 2003 Aug 1;194(3):187-97 [14502431.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Oncogene. 2004 Jun 3;23(26):4646-54 [15064707.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):655-63 [7180965.001]
  • [Cites] J Biol Chem. 1987 Jun 25;262(18):8696-701 [3036821.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;56(4):237-45 [2565618.001]
  • [Cites] Mod Pathol. 1993 Jul;6(4):449-56 [8415591.001]
  • [Cites] J Urol. 1995 Sep;154(3):964-7 [7637102.001]
  • [Cites] Semin Oncol. 2000 Apr;27(2):124-37 [10768592.001]
  • (PMID = 17449941.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN7 protein, human; 0 / Claudins; 0 / Membrane Proteins; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2693599
  •  go-up   go-down


8. Huo L, Sugimura J, Tretiakova MS, Patton KT, Gupta R, Popov B, Laskin WB, Yeldandi A, Teh BT, Yang XJ: C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas. Hum Pathol; 2005 Mar;36(3):262-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas.
  • Recently, KIT has been reported to be a marker for chromophobe renal cell carcinoma (RCC) and renal angiomyolipoma.
  • However, expression of this molecule has not been adequately studied in other renal tumors, particularly oncocytoma, which may morphologically resemble chromophobe RCC.
  • In this study, we analyzed c- kit messenger RNA (mRNA) levels in 17 chromophobe RCCs and 20 renal oncocytomas obtained from complementary DNA (cDNA) microarrays.
  • Furthermore, comprehensive immunohistochemical analysis of KIT protein using a monoclonal antibody was performed in 226 renal tumors including chromophobe RCC (n=40), oncocytoma (n=41), clear-cell RCC (n=40), renal angiomyolipoma (n=29), and papillary RCC (n=21) on tissue microarrays (TMAs) and was compared with immunostaining results from 25 chromophobe RCCs and 30 oncocytomas using standard sections.
  • All chromophobe RCCs and oncocytomas showed significant overexpression of c- kit mRNA.
  • The average increase of mRNA compared with normal kidney tissue was 7.4-fold for chromophobe RCCs and 7.4-fold for oncocytomas.
  • Immunohistochemical expression of KIT was found in most chromophobe RCCs (95% in TMAs and 96% in conventional sections) and oncocytomas (88% in TMAs and 100% in conventional sections) but was infrequently observed in renal angiomyolipomas (17%), papillary RCCs (5%), and clear-cell RCCs (3%).
  • Furthermore, the average KIT immunoreactivity in TMAs was stronger in chromophobe RCC (1.93) and oncocytoma (2.07) than in other subtypes of renal tumors tested, including angiomyolipomas (0.17), papillary RCCs (0.05), and clear-cell RCCs (0.03).
  • In conclusion, we found a significant elevation of c- kit mRNA by cDNA expression microarrays and overexpression of KIT protein by immunohistochemistry not only in chromophobe RCCs but also in oncocytomas.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Carcinoma, Renal Cell / genetics. Gene Expression. Kidney Neoplasms / genetics. Proto-Oncogene Proteins c-kit / genetics. RNA, Messenger / analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15791570.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


9. Okoń K: Glypican-3 is expressed in chromophobe renal cell carcinomas. Pol J Pathol; 2008;59(1):15-20
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glypican-3 is expressed in chromophobe renal cell carcinomas.
  • The reactivity was particularly evident in chromophobe renal cell carcinomas (32/40).
  • [MeSH-minor] Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18655366.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPC3 protein, human; 0 / Glypicans
  •  go-up   go-down


10. Okoń K, Sińczak-Kuta A: Nuclear morphometry as a tool of limited capacity for distinguishing renal oncocytoma from chromophobe carcinoma. Pol J Pathol; 2008;59(1):9-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear morphometry as a tool of limited capacity for distinguishing renal oncocytoma from chromophobe carcinoma.
  • The principal types of renal tumors include malignant clear cell renal cell carcinoma, chromophobe carcinoma (ChRCC), papillary carcinoma and benign oncocytoma (RO) and adenoma.
  • Both oncocytoma and chromophobe carcinoma are characterized by a solid growth pattern of cell with abundant cytoplasm and in some cases may be difficult to distinguish based on histology only.
  • The material for the study consisted of 58 chromophobe carcinomas and 16 oncocytomas.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Carcinoma, Renal Cell / diagnosis. Cell Nucleus / pathology. Kidney Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18655365.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


11. Karslioğlu Y, Günal A, Kurt B, Ongürü O, Ozcan A: Fractal dimension of microvasculature in renal oncocytomas and chromophobe renal cell carcinomas. Pathol Res Pract; 2009;205(10):677-81
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractal dimension of microvasculature in renal oncocytomas and chromophobe renal cell carcinomas.
  • The aim of this study was to evaluate and compare the microvascular architectural complexity in oncocytomas and chromophobe renal cell carcinomas (ChRCCs) by fractal box-counting on CD34-labeled slides.
  • [MeSH-major] Adenoma, Oxyphilic / blood supply. Carcinoma, Renal Cell / blood supply. Fractals. Kidney Neoplasms / blood supply. Microvessels / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19362432.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Adley BP, Gupta A, Lin F, Luan C, Teh BT, Yang XJ: Expression of kidney-specific cadherin in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol; 2006 Jul;126(1):79-85
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of kidney-specific cadherin in chromophobe renal cell carcinoma and renal oncocytoma.
  • Kidney-specific cadherin (Ksp-cad) recently was proposed to differentiate chromophobe renal cell carcinoma (RCC) from oncocytoma based on a finding of Ksp-cad expression in 97% of chromophobe RCCs but only 3% of oncocytomas.
  • Ksp-cad messenger RNA (mRNA) levels were examined in 158 renal tumors, including 15 chromophobe RCCs and 15 oncocytomas.
  • Immunohistochemical analysis was performed on tissue microarrays containing 125 renal tumors, including 36 chromophobe RCCs and 41 oncocytomas.
  • Ksp-cad mRNA compared with normal kidney tissue was 89% in chromophobe RCC and 64% in oncocytoma.
  • Furthermore, 31 of 36 chromophobe RCCs and 31 of 41 oncocytomas showed Ksp-cad immunoreactivity.
  • Ksp-cad was present in chromophobe RCCs and oncocytomas at mRNA and protein levels, providing strong evidence that Ksp-cad immunohistochemical analysis cannot be used in differentiating these tumors.
  • [MeSH-major] Adenoma, Oxyphilic / metabolism. Cadherins / metabolism. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism


13. Rosenkrantz AB, Hindman N, Fitzgerald EF, Niver BE, Melamed J, Babb JS: MRI features of renal oncocytoma and chromophobe renal cell carcinoma. AJR Am J Roentgenol; 2010 Dec;195(6):W421-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI features of renal oncocytoma and chromophobe renal cell carcinoma.
  • OBJECTIVE: The purpose of this study was to retrospectively describe the MRI features of the pathologically related entities renal oncocytoma and chromophobe renal cell carcinoma (RCC).
  • MATERIALS AND METHODS: Twenty-eight cases of histologically proven renal oncocytoma and 15 of chromophobe RCC evaluated with preoperative MRI from January 2003 through June 2009 at our institution were independently reviewed for an array of MRI features by two radiologists blinded to the final histopathologic diagnosis.
  • These features were tabulated and compared between chromophobe RCC and renal oncocytoma by use of the Mann-Whitney test and binary logistic regression.
  • RESULTS: Renal oncocytoma and chromophobe RCC showed no significant difference in size or any of 16 qualitative imaging features (p = 0.0842-1.0, reader 1; p = 0.0611-1.0, reader 2).
  • A central scar and segmental enhancement inversion (a recently described finding in which early contrast-enhanced images show relatively more enhanced and less enhanced intralesional components with inversion of their relative enhancement on later images) were observed by both readers in at least 10% of cases of both renal oncocytoma and of chromophobe RCC with no significant difference between the two entities (p = 0.2092-0.2960).
  • CONCLUSION: We have presented the largest series to date of the MRI features of both renal oncocytoma and chromophobe RCC.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Magnetic Resonance Imaging / methods


14. Garcia E, Li M: Caveolin-1 immunohistochemical analysis in differentiating chromophobe renal cell carcinoma from renal oncocytoma. Am J Clin Pathol; 2006 Mar;125(3):392-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin-1 immunohistochemical analysis in differentiating chromophobe renal cell carcinoma from renal oncocytoma.
  • Chromophobe renal cell carcinoma (ChRCC) and oncocytoma might mimic each other histologically.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Carcinoma, Renal Cell / pathology. Caveolin 1 / analysis. Kidney Neoplasms / pathology


15. Adley BP, Papavero V, Sugimura J, Teh BT, Yang XJ: Diagnostic value of cytokeratin 7 and parvalbumin in differentiating chromophobe renal cell carcinoma from renal oncocytoma. Anal Quant Cytol Histol; 2006 Aug;28(4):228-36
Hazardous Substances Data Bank. IRON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of cytokeratin 7 and parvalbumin in differentiating chromophobe renal cell carcinoma from renal oncocytoma.
  • STUDY DESIGN: CK7 and parvalbumin mRNA expression levels in 23 oncocytomas and 32 chromophobe renal cell carcinomas (RCCs) were examined using gene expression microarrays.
  • Immunohistochemistry was performed using monoclonal antibodies specific for CK7 or parvalbumin in 41 chromophobe RCCs and 55 oncocytomas.
  • RESULTS: CK7 mRNA was overexpressed in 18 of 32 chromophobe RCCs but only 3 of 23 oncocytomas.
  • Parvalbumin mRNA was overexpressed in 15 of 32 chromophobe RCCs and only 4 of 23 oncocytomas.
  • In contrast, CK7 mRNA underexpression was noted in 13 of 23 oncocytomas and only 6 of 32 chromophobe RCCs, while parvalbumin underexpression was seen in 14 of 23 oncocytomas but only 6 of 32 chromophobe RCCs.
  • By immunohistochemistry, 27 of 41 (66%) chromophobe RCCs expressed CK7 diffusely compared to only 3 of 55 (5%) oncocytomas.
  • Diffuse parvalbumin expression was seen in all 41 of 41 (100%) chromophobe RCCs and only in 26 of 55 (47%) oncocytomas.
  • CONCLUSION: Both mRNA and protein expression levels of CK7 appear significantly higher in chromophobe RCC compared to oncocytoma (p < 0.001).
  • Our study provides further evidence that CK7 and parvalbumin immunostains may be useful in differentiating oncocytoma from chromophobe RCC in problematic cases.


16. Waldert M, Klatte T, Haitel A, Ozsoy M, Schmidbauer J, Marberger M, Remzi M: Hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomes. Eur Urol; 2010 Apr;57(4):661-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomes.
  • BACKGROUND: Modern histopathology is able to differentiate chromophobe renal cell carcinomas (cRCCs), oncocytomas, and chromophobe-oncocytic hybrid RCCs; however, the true frequency and clinical courses of these tumors remain unclear.
  • [MeSH-minor] Adenoma, Oxyphilic / chemistry. Adenoma, Oxyphilic / mortality. Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / surgery. Adult. Aged. Aged, 80 and over. Austria. Biomarkers, Tumor / analysis. Biopsy. Disease-Free Survival. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Keratin-7 / analysis. Kidney Neoplasms / chemistry. Kidney Neoplasms / mortality. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Nephrectomy. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • [CommentIn] Eur Urol. 2010 Apr;57(4):665 [19477585.001]
  • [CommentIn] Eur Urol. 2010 Apr;57(4):666 [19477584.001]
  • (PMID = 19477583.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT7 protein, human; 0 / Keratin-7; Oncocytoma, renal
  •  go-up   go-down


17. Wang HY, Mills SE: KIT and RCC are useful in distinguishing chromophobe renal cell carcinoma from the granular variant of clear cell renal cell carcinoma. Am J Surg Pathol; 2005 May;29(5):640-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIT and RCC are useful in distinguishing chromophobe renal cell carcinoma from the granular variant of clear cell renal cell carcinoma.
  • The distinction between chromophobe renal cell carcinoma, the granular cell variant of clear cell renal cell carcinoma, and renal oncocytoma is a common diagnostic dilemma.
  • KIT was 100% positive in chromophobe renal cell carcinoma (11 of 11) and renal oncocytoma (12 of 12).
  • RCC was observed in more than 80% of the granular cell variant of clear cell renal cell carcinoma (5 of 6) but was negative in all chromophobe renal cell carcinomas (0 of 11) and renal oncocytomas (0 of 12).
  • CD10 was expressed in 100% of the granular cell variant of clear cell renal cell carcinoma (6 of 6), 72% of chromophobe renal cell carcinomas (8 of 11), and 58% of renal oncocytomas (7 of 12).
  • RON was 100% positive in the chromophobe renal cell carcinomas (11 of 11) and renal oncocytomas (12 of 12) but only 50% positive in the granular cell variant of clear cell renal cell carcinoma (3 of 6).
  • Colloidal iron was diffusely and strongly positive in more than 80% of the chromophobe renal cell carcinomas (9 of 11), focally and weakly positive in 41% of the renal oncocytomas (5 of 12) but negative in all granular cell variant of clear cell renal cell carcinoma (0 of 6).
  • 1) KIT is a very sensitive marker for both chromophobe renal cell carcinoma and renal oncocytoma;.
  • 2) immunohistochemistry using antibodies to KIT combined with RCC was sufficient to discriminate between chromophobe renal cell carcinoma and the granular cell variant of clear cell renal cell carcinoma; and 3) neither RON, nor KIT, nor a combination of this panel can be used to distinguish chromophobe renal cell carcinoma from renal oncocytoma.
  • Colloidal iron staining aided in this distinction for the majority of the chromophobe renal cell carcinomas (more than 80% positive) and renal oncocytomas (close to 60% negative).
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenoma, Oxyphilic / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Mitogen-Activated Protein Kinases. Proto-Oncogene Proteins c-kit

  • Genetic Alliance. consumer health - Chromophobe Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832088.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; EC 2.7.1.- / RON protein; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.11.22 / MOK protein, human; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


18. Mai KT, Teo I, Belanger EC, Robertson SJ, Marginean EC, Islam S: Progesterone receptor reactivity in renal oncocytoma and chromophobe renal cell carcinoma. Histopathology; 2008 Feb;52(3):277-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progesterone receptor reactivity in renal oncocytoma and chromophobe renal cell carcinoma.
  • AIMS: To investigate the reactivity for oestrogen and progesterone receptors (ER and PR) in renal oncocytoma (RO) and chromophobe renal cell carcinoma (CHRCC).
  • [MeSH-major] Adenoma, Oxyphilic / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism. Receptors, Progesterone / metabolism


19. Mazal PR, Exner M, Haitel A, Krieger S, Thomson RB, Aronson PS, Susani M: Expression of kidney-specific cadherin distinguishes chromophobe renal cell carcinoma from renal oncocytoma. Hum Pathol; 2005 Jan;36(1):22-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of kidney-specific cadherin distinguishes chromophobe renal cell carcinoma from renal oncocytoma.
  • Distinguishing renal oncocytoma from chromophobe and other renal carcinomas is essential, considering their differing biological potentials.
  • Although renal oncocytoma is considered a benign tumor, chromophobe renal cell carcinoma has potentially malignant biological behavior.
  • We report a novel immunohistochemical approach based on the expression of a recently described kidney-specific cadherin (Ksp-cadherin) for the differential diagnosis of these 2 tumors.
  • We compared Ksp-cadherin expression in 212 renal tumors, including 102 clear cell renal carcinomas, 46 papillary renal cell carcinomas, 30 chromophobe carcinomas, 3 collecting duct carcinomas, and 31 oncocytomas.
  • We found that chromophobe renal cell carcinomas consistently (96.7% of cases) demonstrated a distinctive membrane pattern of Ksp-cadherin expression, whereas renal oncocytomas (3.2%), clear cell renal cell carcinomas (0%), papillary renal cell carcinomas (2.2%), and collecting duct carcinomas (0%) usually did not express Ksp-cadherin.
  • Whereas CK7 was detected in different types of renal cell carcinomas, Ksp-cadherin was expressed almost exclusively in chromophobe renal cell carcinomas.
  • Immunohistochemical analysis of Ksp-cadherin offers a fast, reliable approach for the distinguishing between renal oncocytoma and chromophobe renal cell carcinoma that is applicable for routine pathology laboratory studies without the need for time-consuming and costly ancillary studies.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Papillary / metabolism. Adenoma, Oxyphilic / metabolism. Biomarkers, Tumor / analysis. Cadherins / biosynthesis. Kidney Neoplasms / metabolism


20. Sukov WR, Ketterling RP, Lager DJ, Carlson AW, Sinnwell JP, Chow GK, Jenkins RB, Cheville JC: CCND1 rearrangements and cyclin D1 overexpression in renal oncocytomas: frequency, clinicopathologic features, and utility in differentiation from chromophobe renal cell carcinoma. Hum Pathol; 2009 Sep;40(9):1296-303
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CCND1 rearrangements and cyclin D1 overexpression in renal oncocytomas: frequency, clinicopathologic features, and utility in differentiation from chromophobe renal cell carcinoma.
  • The histologic features of renal oncocytoma may overlap with those of chromophobe renal cell carcinoma.
  • We evaluated a series of 63 renal oncocytomas and 36 chromophobe renal cell carcinomas and assessed the clinical features, cyclin D1 overexpression by immunohistochemistry, and alterations of the CCND1 gene by fluorescence in situ hybridization.
  • All 36 chromophobe renal cell carcinomas were negative for cyclin D1 overexpression and alterations of CCND1.
  • The data also show that cyclin D1 overexpression and CCND1 rearrangements by fluorescence in situ hybridization are absent in chromophobe renal cell carcinoma, suggesting that these are useful when differentiating between renal oncocytoma and chromophobe renal cell carcinoma.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Carcinoma, Renal Cell / genetics. Cyclin D1 / genetics. Gene Rearrangement. Kidney Neoplasms / genetics


21. Osunkoya AO, Cohen C, Lawson D, Picken MM, Amin MB, Young AN: Claudin-7 and claudin-8: immunohistochemical markers for the differential diagnosis of chromophobe renal cell carcinoma and renal oncocytoma. Hum Pathol; 2009 Feb;40(2):206-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-7 and claudin-8: immunohistochemical markers for the differential diagnosis of chromophobe renal cell carcinoma and renal oncocytoma.
  • In a recent oligonucleotide microarray study, we identified claudin-7 and claudin-8 as candidate markers to distinguish chromophobe renal cell carcinoma from other renal tumors, including oncocytoma.
  • Distinction of these lesions can be difficult by light microscopy but is clinically important because chromophobe renal cell carcinoma has malignant biological potential, whereas renal oncocytoma is benign.
  • Claudin-7 and claudin-8 expression was studied by immunohistochemistry in 11 chromophobe renal cell carcinomas and 17 oncocytomas using formalin-fixed paraffin-embedded tissue sections of tumor with adjacent nonneoplastic kidney.
  • Claudin-7 protein was expressed in a membranous pattern in 10 of 11 chromophobe renal cell carcinomas and 4 of 17 oncocytomas (P < .01).
  • In chromophobe renal cell carcinoma, 0 of 11 cases showed cytoplasmic, 3 of 11 membranous, and 8 of 11 negative reactions (P < .01).
  • The immunohistochemical pattern of membranous claudin-7 and negative claudin-8 was seen in 7 of 11 chromophobe renal cell carcinomas and 1 of 17 oncocytomas (63% sensitivity, 84% specificity, 88% positive predictive value for chromophobe renal cell carcinoma).
  • Negative claudin-7 and cytoplasmic claudin-8 were observed in 10 of 17 oncocytomas and 0 of 11 chromophobe renal cell carcinomas (59% sensitivity, 100% specificity and positive predictive value for oncocytoma).
  • The distal nephron proteins claudin-7 and claudin-8 have potential use as immunohistochemical biomarkers in the differential diagnosis of chromophobe renal cell carcinoma and oncocytoma.
  • Expression of claudin-7 and claudin-8 may reflect the relationship of chromophobe renal cell carcinoma and oncocytoma to intercalated cells of the cortical collecting duct.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Membrane Proteins / biosynthesis


22. Aslam MI, Spencer L, Garcea G, Pollard C, Metcalfe MS, Harrison RF, Dennison AR: A case of liver metastasis from an oncocytoma with a focal area of chromophobe renal cell carcinoma: a wolf in sheep's clothing. Int J Surg Pathol; 2009 Apr;17(2):158-62
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of liver metastasis from an oncocytoma with a focal area of chromophobe renal cell carcinoma: a wolf in sheep's clothing.
  • There are reports of subtypes of renal tumors, with similar histological morphology to oncocytoma, but with malignant potential, one of these tumors is the eosinophilic variant of chromophobe renal cell carcinoma.
  • A rare case of a liver metastasis from a focal area of eosinophilic variant of chromophobe renal cell carcinoma mixed in oncocytoma in a 69-year-old woman is reported.
  • Although some renal tumors may contain oncocytoma and eosinophilic variant of chromophobe renal cell carcinoma histology, caution should be exercised while diagnosing oncocytomas in needle biopsies as there may be unsampled area of chromophobe carcinoma which has a potential for metastatic spread representing a wolf in sheep's clothing.
  • [MeSH-major] Adenoma, Oxyphilic / secondary. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Liver Neoplasms / secondary


23. Liu L, Qian J, Singh H, Meiers I, Zhou X, Bostwick DG: Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. Arch Pathol Lab Med; 2007 Aug;131(8):1290-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis.
  • CONTEXT: The separation of chromophobe renal cell carcinoma, oncocytoma, and clear cell renal cell carcinoma using light microscopy remains problematic in some cases.
  • OBJECTIVE: To determine a practical immunohistochemical panel for the differential diagnosis of chromophobe carcinoma.
  • DESIGN: Vimentin, glutathione S-transferase alpha (GST-alpha), CD10, CD117, cytokeratin (CK) 7, and epithelial cell adhesion molecule (EpCAM) were investigated in 22 cases of chromophobe carcinoma, 17 cases of oncocytoma, and 45 cases of clear cell carcinoma.
  • CD10 staining was more frequently detected in clear cell carcinoma (91%) than in chromophobe carcinoma (45%) and oncocytoma (29%).
  • CD117 was strongly expressed in chromophobe carcinoma (82%) and oncocytoma (100%), whereas none of the cases of clear cell carcinomas were immunoreactive.
  • Cytokeratin 7 was positive in 18 (86%) of 22 cases of chromophobe carcinoma, whereas all oncocytomas were negative for CK7.
  • EpCAM protein was expressed in all 22 cases of chromophobe carcinoma in more than 90% of cells, whereas all EpCAM-positive oncocytomas (5/17; 29%) displayed positivity in single cells or small cell clusters.
  • CONCLUSIONS: Using the combination of 3 markers (vimentin, GST-alpha, and EpCAM), we achieved 100% sensitivity and 100% specificity for the differential diagnosis of chromophobe carcinoma, oncocytoma, and clear cell carcinoma.
  • The pattern of "vimentin(-)/GST-alpha(-)" effectively excluded clear cell carcinoma, and homogeneous EpCAM expression confirmed the diagnosis of chromophobe carcinoma rather than oncocytoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenoma, Oxyphilic / diagnosis. Biomarkers, Tumor / analysis. Carcinoma, Renal Cell / diagnosis. Immunoenzyme Techniques / methods. Kidney Neoplasms / diagnosis. Neoplasm Proteins / analysis


24. Hornsby CD, Cohen C, Amin MB, Picken MM, Lawson D, Yin-Goen Q, Young AN: Claudin-7 immunohistochemistry in renal tumors: a candidate marker for chromophobe renal cell carcinoma identified by gene expression profiling. Arch Pathol Lab Med; 2007 Oct;131(10):1541-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-7 immunohistochemistry in renal tumors: a candidate marker for chromophobe renal cell carcinoma identified by gene expression profiling.
  • In particular, chromophobe renal cell carcinoma (RCC) is difficult to distinguish from oncocytoma.
  • This differential diagnosis is important because chromophobe RCC is malignant, whereas oncocytoma is benign.
  • Furthermore, chromophobe RCC has distinct malignant potential and prognosis compared with eosinophilic variants of other RCC subtypes.
  • Immunohistochemistry is useful for distinguishing chromophobe RCC from other subtypes of renal carcinoma, but no expression marker reliably separates chromophobe RCC from oncocytoma.
  • OBJECTIVE: In a previous gene expression microarray analysis of renal tumor subtypes, we found the distal nephron markers claudin-7 and claudin-8 to be overexpressed in chromophobe RCC versus oncocytoma and other tumor subtypes.
  • DESIGN: Immunohistochemical analysis of claudin-7 in 36 chromophobe RCCs, 43 oncocytomas, 42 clear cell RCCs, and 29 papillary RCCs.
  • RESULTS: Membranous claudin-7 expression was detected in 67% chromophobe RCCs, compared with 0% clear cell RCCs, 28% papillary RCCs, and 26% oncocytomas (P < .001).
  • CONCLUSIONS: Based on microarray and immunohistochemical data, we propose claudin-7 to be a candidate expression marker for distinguishing chromophobe RCC from other renal tumor subtypes, including the morphologically similar oncocytoma.
  • [MeSH-minor] Adenoma, Oxyphilic / diagnosis. Claudins. Diagnosis, Differential. Immunohistochemistry. RNA, Messenger / metabolism. RNA, Neoplasm / analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922590.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 U54 CA119338-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN7 protein, human; 0 / Claudins; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


25. Yusenko MV, Kuiper RP, Boethe T, Ljungberg B, van Kessel AG, Kovacs G: High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. BMC Cancer; 2009;9:152
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas.
  • BACKGROUND: The diagnosis of benign renal oncocytomas (RO) and chromophobe renal cell carcinomas (RCC) based on their morphology remains uncertain in several cases.
  • We demonstrated that chromosomal gene expression biases might correlate with chromosomal abnormalities found in chromophobe RCCs and ROs.
  • The vast majority genes downregulated in chromophobe RCC were mapped to chromosomes 2, 6, 10, 13 and 17.
  • However, most of the genes overexpressed in chromophobe RCCs were located to chromosomes without any copy number changes indicating a transcriptional regulation as a main event.
  • However, we have identified loss of chromosome 2, 10, 13, 17 and 21 as discriminating alteration between chromophobe RCCs and ROs.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Carcinoma, Renal Cell / genetics. Gene Dosage. Gene Expression Profiling. Kidney Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1542-52 [12459621.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):712-7 [12118108.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):925-32 [12598325.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6810-8 [14555994.001]
  • [Cites] Int J Cancer. 2004 Apr 10;109(3):472-5 [14961590.001]
  • [Cites] Histopathology. 2004 Jun;44(6):542-6 [15186268.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4117-21 [15205321.001]
  • [Cites] Cancer Genet Cytogenet. 1988 Apr;31(2):211-5 [3349439.001]
  • [Cites] J Cancer Res Clin Oncol. 1990;116(4):318-23 [2202729.001]
  • [Cites] Genes Chromosomes Cancer. 1992 Apr;4(3):267-8 [1382570.001]
  • [Cites] Histopathology. 1993 Jan;22(1):1-8 [8436337.001]
  • [Cites] J Urol. 1994 Aug;152(2 Pt 1):471-2 [8015093.001]
  • [Cites] Am J Pathol. 1994 Aug;145(2):356-64 [7519827.001]
  • [Cites] J Urol. 1995 Sep;154(3):964-7 [7637102.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1756-61 [8859189.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Dec;17(4):199-204 [8946201.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):2081-8 [8952540.001]
  • [Cites] Lab Invest. 1997 Feb;76(2):203-8 [9042156.001]
  • [Cites] J Pathol. 1997 Feb;181(2):136-9 [9120715.001]
  • [Cites] Am J Hum Genet. 1997 Nov;61(5):995-9 [9345110.001]
  • [Cites] J Pathol. 1997 Oct;183(2):131-3 [9390023.001]
  • [Cites] J Pathol. 1998 Jan;184(1):58-62 [9582528.001]
  • [Cites] Histopathology. 2004 Dec;45(6):593-602 [15569050.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):161-9 [15467713.001]
  • [Cites] Hum Pathol. 2005 Jan;36(1):22-8 [15712178.001]
  • [Cites] J Mol Diagn. 2005 May;7(2):206-18 [15858144.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6071-9 [16024607.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6558-66 [16166433.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):6937-45 [17145811.001]
  • [Cites] PLoS Genet. 2008;4(9):e1000176 [18773095.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1639-51 [11337362.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 15;128(2):161-3 [11463457.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):957-60 [11861363.001]
  • [Cites] Histopathology. 2002 Mar;40(3):300-2 [11895501.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):199-205 [12548166.001]
  • (PMID = 19445733.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE11151
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2686725
  •  go-up   go-down


26. Rohan S, Tu JJ, Kao J, Mukherjee P, Campagne F, Zhou XK, Hyjek E, Alonso MA, Chen YT: Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes. Clin Cancer Res; 2006 Dec 1;12(23):6937-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes.
  • PURPOSE: To compare gene expression profiles of chromophobe renal cell carcinoma (RCC) and benign oncocytoma, aiming at identifying differentially expressed genes.
  • EXPERIMENTAL DESIGN: Nine cases each of chromophobe RCC and oncocytoma were analyzed by oligonucleotide microarray.
  • RESULTS: Unsupervised hierarchical clustering separated the chromophobe RCC and oncocytoma into two distinct groups.
  • By a combination of data analysis approaches, we identified 11 candidate genes showing consistent differential expression between chromophobe RCC and oncocytoma.
  • Immunohistochemical analysis revealed selective expression of MAL2 and claudin 8 in distal renal tubules, with MAL2 antibody showing differential expression between chromophobe RCC and oncocytoma.
  • Functional analyses suggest that genes encoding tight junction proteins and vesicular membrane trafficking proteins, normally expressed in distal nephrons, are retained in chromophobe RCC and lost or consistently down-regulated in oncocytoma, indicating that these two tumor types, believed to be both derived from distal tubules, are likely distinctive in their histogenesis.
  • CONCLUSIONS: We showed that chromophobe RCC and oncocytoma are distinguishable by mRNA expression profiles and a panel of gene products potentially useful as diagnostic markers were identified.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Carcinoma, Renal Cell / genetics. Gene Expression Profiling. Kidney Neoplasms / genetics. Membrane Proteins / genetics. Thyroid Neoplasms / genetics. Vesicular Transport Proteins / genetics

  • Genetic Alliance. consumer health - Chromophobe Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145811.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AP1M2 protein, human; 0 / Adaptor Protein Complex 1; 0 / Adaptor Protein Complex mu Subunits; 0 / FLJ20171 protein, human; 0 / MAL2 protein, human; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / Myelin and Lymphocyte-Associated Proteolipid Proteins; 0 / PROM2 protein, human; 0 / Proteolipids; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / Vesicular Transport Proteins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / prostasin
  •  go-up   go-down


27. Yusenko MV, Ruppert T, Kovacs G: Analysis of differentially expressed mitochondrial proteins in chromophobe renal cell carcinomas and renal oncocytomas by 2-D gel electrophoresis. Int J Biol Sci; 2010;6(3):213-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of differentially expressed mitochondrial proteins in chromophobe renal cell carcinomas and renal oncocytomas by 2-D gel electrophoresis.
  • Renal oncocytomas (RO) and chromophobe renal cell carcinomas (RCC) display morphological and functional alterations of the mitochondria.
  • Previous studies showed that accumulation of mitochondria in ROs is associated with somatic mutations of mitochondrial DNA (mtDNA) resulting in decreased activity of the respiratory chain complex I, whereas in chromophobe RCC only heteroplasmic mtDNA mutations were found.
  • To identify proteins associated with these changes, for the first time we have compared the mitochondrial proteomes of mitochondria isolated from ROs and chromophobe RCCs as well as from normal kidney tissues by two-dimensional polyacrylamide gel electrophoresis.
  • In chromophobe RCCs downregulation of ATP5A1, the alpha subunit of complex V, has been observed, but no changes in expression of other complexes of the respiratory chain were detected.
  • To confirm the role of respiratory chain complex alterations in the morphological and/or functional changes in chromophobe RCCs and ROs, further studies will be necessary.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / metabolism. Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / genetics. Kidney Neoplasms / metabolism. Mitochondrial Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proteomics. 2004 Aug;4(8):2252-60 [15274119.001]
  • [Cites] Genes Chromosomes Cancer. 1989 Sep;1(1):79-82 [2487148.001]
  • [Cites] Genes Chromosomes Cancer. 1992 Apr;4(3):267-8 [1382570.001]
  • [Cites] J Urol. 1994 Aug;152(2 Pt 1):471-2 [8015093.001]
  • [Cites] Am J Pathol. 1994 Aug;145(2):356-64 [7519827.001]
  • [Cites] J Urol. 1995 Sep;154(3):964-7 [7637102.001]
  • [Cites] Biochim Biophys Acta. 1996 Aug 23;1316(3):203-9 [8781539.001]
  • [Cites] Lab Invest. 1997 Feb;76(2):203-8 [9042156.001]
  • [Cites] J Pathol. 1997 Feb;181(2):136-9 [9120715.001]
  • [Cites] J Pathol. 1997 Oct;183(2):131-3 [9390023.001]
  • [Cites] Folia Morphol (Warsz). 2004 Nov;63(4):407-12 [15712135.001]
  • [Cites] FEBS J. 2005 Jun;272(11):2892-900 [15943820.001]
  • [Cites] Int J Oncol. 2006 Jan;28(1):103-10 [16327985.001]
  • [Cites] Mitochondrion. 2006 Jun;6(3):105-17 [16714150.001]
  • [Cites] Biochim Biophys Acta. 2006 May-Jun;1757(5-6):518-24 [16829229.001]
  • [Cites] Adv Exp Med Biol. 2007;594:14-26 [17205671.001]
  • [Cites] Biochimie. 2007 Sep;89(9):1080-8 [17466430.001]
  • [Cites] J Bioenerg Biomembr. 2007 Jun;39(3):235-41 [17665292.001]
  • [Cites] Hum Mol Genet. 2008 Apr 1;17(7):986-95 [18156159.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2270-5 [18413815.001]
  • [Cites] BMC Cancer. 2009;9:152 [19445733.001]
  • [Cites] Proteomics. 2009 Jun;9(11):3209-14 [19415664.001]
  • [Cites] Int J Biol Sci. 2009;5(6):517-27 [19680475.001]
  • [Cites] Basic Res Cardiol. 2003 Jul;98(4):219-27 [12835951.001]
  • [Cites] Carcinogenesis. 2003 Sep;24(9):1461-6 [12844484.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6810-8 [14555994.001]
  • [Cites] Int J Cancer. 2004 Apr 10;109(3):472-5 [14961590.001]
  • [Cites] Histopathology. 2004 Jun;44(6):542-6 [15186268.001]
  • [Cites] Nature. 1999 Dec 16;402(6763):716-7 [10617185.001]
  • [Cites] Electrophoresis. 2000 Oct;21(16):3427-40 [11079563.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1639-51 [11337362.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 15;128(2):161-3 [11463457.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):759-68 [12016148.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Nov;35(3):256-60 [12353267.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14772-7 [12417764.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):925-32 [12598325.001]
  • [Cites] Genome Res. 2001 Nov;11(11):1861-70 [11691851.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):957-60 [11861363.001]
  • (PMID = 20440404.001).
  • [ISSN] 1449-2288
  • [Journal-full-title] International journal of biological sciences
  • [ISO-abbreviation] Int. J. Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / DNA, Mitochondrial; 0 / Membrane Proteins; 0 / Mitochondrial Proteins; 0 / Proteome; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.3.14 / oligomycin sensitivity-conferring protein
  • [Other-IDs] NLM/ PMC2862395
  • [Keywords] NOTNLM ; 2-D PAGE. / chromophobe renal cell carcinoma / mass spectrometry / mitochondria / renal oncocytoma
  •  go-up   go-down


28. Blanco L, Larrinaga G, Pérez I, López JI, Gil J, Agirregoitia E, Varona A: Acid, basic, and neutral peptidases present different profiles in chromophobe renal cell carcinoma and in oncocytoma. Am J Physiol Renal Physiol; 2008 Apr;294(4):F850-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acid, basic, and neutral peptidases present different profiles in chromophobe renal cell carcinoma and in oncocytoma.
  • Now, to gain insight into the reasons that lead the various RCC types to behave very differently with regard to aggressiveness and response to anticancer treatments, we analyzed subsets of chromophobe renal cell carcinoma (ChRCC), and renal oncocytoma (RO), a benign tumor; as well as different grades and stages of CCRCCs.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Carcinoma, Renal Cell / genetics. Kidney Neoplasms / genetics. Peptide Hydrolases / genetics


29. Brunelli M, Delahunt B, Gobbo S, Tardanico R, Eccher A, Bersani S, Cossu-Rocca P, Parolini C, Balzarini P, Menestrina F, Cheng L, Eble JN, Martignoni G: Diagnostic usefulness of fluorescent cytogenetics in differentiating chromophobe renal cell carcinoma from renal oncocytoma: a validation study combining metaphase and interphase analyses. Am J Clin Pathol; 2010 Jan;133(1):116-26
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic usefulness of fluorescent cytogenetics in differentiating chromophobe renal cell carcinoma from renal oncocytoma: a validation study combining metaphase and interphase analyses.
  • We investigated the usefulness of interphase fluorescence in situ hybridization (FISH) analysis to differentiate between 11 chromophobe renal carcinomas and 12 renal oncocytomas, showing different clinical outcomes, when compared with conventional metaphase cytogenetics by karyotyping.
  • Karyotypically, 3 chromophobe renal cell carcinomas showed losses of chromosomes, 3 were polyploid, 1 was normal, and 4 failed to grow.
  • FISH on chromophobe renal cell carcinomas showed a high percentage of cases (10/11 [91%]) with multiple numeric losses among chromosomes 1, 2, 6, 10, and 17; this interphase pattern was observed irrespective of the 3 different metaphase karyotypes.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Carcinoma, Renal Cell / diagnosis. Chromosome Aberrations. In Situ Hybridization, Fluorescence. Kidney Neoplasms / diagnosis


30. Petersson F, Gatalica Z, Grossmann P, Perez Montiel MD, Alvarado Cabrero I, Bulimbasic S, Swatek A, Straka L, Tichy T, Hora M, Kuroda N, Legendre B, Michal M, Hes O: Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases. Virchows Arch; 2010 Apr;456(4):355-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases.
  • Hybrid oncocytic/chromophobe tumors (HOCT) of the kidney have been described in patients with Birt-Hogg-Dubé syndrome (BHD) and in association with renal oncocytosis without BHD.
  • We have identified and studied 14 cases of HOCT from previously diagnosed renal oncocytomas (398 cases) and chromophobe renal cell carcinomas (351 cases) without evidence of BHD or renal oncocytosis.
  • No pathogenic mutations were found in the VHL, c-kit, PDGFR, and folliculin (FLCN) genes. (1) We have shown that hybrid oncocytic/chromophobe tumors of the kidney do occur, albeit rarely, outside the Birt-Hogg-Dubé syndrome and without associated renal oncocytosis. (2) These tumors constitute a relatively homogenous group with histomorphologic features of both chromophobe renal cell carcinoma and renal oncocytoma. (3) Sporadic hybrid oncocytic/chromophobe renal tumors are characterized by multiple numerical aberrations (both mono- and polysomies) of chromosomes 1, 2, 6, 9, 10, 13, 17, 21, and 22 and lack of mutations in the VHL, c-kit, PDGFRA, and FLCN genes. (4) The tumors seem to behave indolently as no evidence of malignant behavior was documented in our series, although admittedly, the follow-up was too short to fully elucidate the biological nature of this rare neoplasm.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / pathology. Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / genetics. Kidney Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2005 May;173(5):1482-6 [15821464.001]
  • [Cites] Clin Genet. 2009 Jun;75(6):537-43 [19320655.001]
  • [Cites] Pathol Int. 2005 Apr;55(4):210-5 [15826248.001]
  • [Cites] J Pathol. 1998 Jan;184(1):58-62 [9582528.001]
  • [Cites] Med Mol Morphol. 2008 Dec;41(4):227-32 [19107613.001]
  • [Cites] Eur Urol. 2010 Apr;57(4):661-5 [19477583.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Dec;17(4):199-204 [8946201.001]
  • [Cites] BJU Int. 2009 May;103(10):1381-4 [19154497.001]
  • [Cites] J Pathol. 2007 Apr;211(5):524-31 [17323425.001]
  • [Cites] Virchows Arch. 2008 Mar;452(3):285-93 [18196270.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):161-9 [15467713.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):498-504 [18246052.001]
  • [Cites] Arch Pathol Lab Med. 2006 Dec;130(12):1865-70 [17149965.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1576-81 [16327429.001]
  • [Cites] Br J Dermatol. 2009 Jun;160(6):1350-3 [19416240.001]
  • [Cites] Am J Pathol. 1989 May;134(5):967-71 [2719081.001]
  • [Cites] Hum Pathol. 2009 Dec;40(12):1813-9 [19733897.001]
  • [Cites] Ultrastruct Pathol. 1993 Sep-Oct;17(5):529-36 [8256297.001]
  • [Cites] Pathol Res Pract. 2005;201(5):385-9 [16047948.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1542-52 [12459621.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23(9):1094-101 [10478670.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2071-7 [3567867.001]
  • [Cites] Ann Diagn Pathol. 2006 Jun;10(3):133-9 [16730306.001]
  • (PMID = 20300772.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / FLCN protein, human; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins; EC 2.3.2.27 / Von Hippel-Lindau Tumor Suppressor Protein; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 6.3.2.- / VHL protein, human
  •  go-up   go-down


31. Brunelli M, Eble JN, Zhang S, Martignoni G, Delahunt B, Cheng L: Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. Mod Pathol; 2005 Feb;18(2):161-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma.
  • That chromophobe renal cell carcinoma has an uncommon eosinophilic variant has been recognized for more than a decade.
  • In sections stained with hematoxylin and eosin, the eosinophilic variant of chromophobe renal cell carcinoma and renal oncocytoma are similar in appearance.
  • While it is well established that chromophobe renal cell carcinoma and renal oncocytoma have different patterns of genetic anomalies, little is known of the genetics of the eosinophilic variant of chromophobe renal cell carcinoma.
  • This study was undertaken to elucidate the genetic lesions of eosinophilic chromophobe renal cell carcinoma and to compare them with those found in classic chromophobe renal cell carcinoma and in renal oncocytoma.
  • A total of 29 renal neoplasms--nine eosinophilic chromophobe renal cell carcinomas, 10 classic chromophobe renal cell carcinomas, and 10 oncocytomas--were investigated by fluorescence in situ hybridization on 5 microm paraffin-embedded tissue sections with centromeric probes for chromosomes 1, 2, 6, 10, and 17.
  • Chromophobe renal cell carcinomas frequently showed loss of chromosomes 1 (70% of classic, 67% of eosinophilic), 2 (90% classic, 56% eosinophilic), 6 (80% classic, 56% eosinophilic), 10 (60% classic, 44% eosinophilic), and 17 (90% classic, 78% eosinophilic); Among the classic chromophobe renal cell carcinomas, only one had no loss of any of the chromosomes, while 50% had loss of all five chromosomes.
  • Among the eosinophilic chromophobe renal cell carcinomas, one of nine had no loss and 44% had loss of all five chromosomes.
  • In conclusion, losses of chromosomes 1, 2, 6, 10, and 17 are frequent in both eosinophilic and classic chromophobe renal cell carcinomas.
  • When the differential diagnostic problem is oncocytoma vs eosinophilic chromophobe renal cell carcinoma, detection of losses of chromosomes 2, 6, 10, or 17 effectively excludes the diagnosis of oncocytoma and supports the diagnosis of chromophobe renal cell carcinoma.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Carcinoma, Renal Cell / pathology. Chromosome Aberrations. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15467713.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. Hes O, Vanecek T, Perez-Montiel DM, Alvarado Cabrero I, Hora M, Suster S, Lamovec J, Curik R, Mandys V, Michal M: Chromophobe renal cell carcinoma with microcystic and adenomatous arrangement and pigmentation--a diagnostic pitfall. Morphological, immunohistochemical, ultrastructural and molecular genetic report of 20 cases. Virchows Arch; 2005 Apr;446(4):383-93
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromophobe renal cell carcinoma with microcystic and adenomatous arrangement and pigmentation--a diagnostic pitfall. Morphological, immunohistochemical, ultrastructural and molecular genetic report of 20 cases.
  • We present clinical, morphological, immunohistochemical, ultrastructural and molecular genetic features of 20 cases of a peculiar form of chromophobe renal cell carcinoma (CRCC) with morphology differing from that of conventional CRCC.
  • They had a typical columnar arrangement with nuclei positioned at the base of the glandular structures and a small amount of a deeply eosinophilic cytoplasm often endowed with brush border facing the lumen of the glands.
  • The important feature of pigmented microcystic chromophobe renal cell carcinoma is a relatively benign biological behavior and the absence of distant metastases and sarcomatoid transformation.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Oxyphil Cells / ultrastructure

  • Genetic Alliance. consumer health - Chromophobe Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1997 Jul;31(1):38-46 [9253623.001]
  • [Cites] Cancer. 1971 Jan;27(1):116-9 [5539620.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):871-83 [9255250.001]
  • [Cites] Am J Clin Pathol. 1987 Mar;87(3):334-41 [2435143.001]
  • [Cites] Am J Surg Pathol. 1995 Mar;19(3):350-6 [7872433.001]
  • [Cites] Am J Clin Pathol. 1974 Jul;62(1):97-103 [4134750.001]
  • [Cites] J Pathol. 1997 Oct;183(2):131-3 [9390023.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):602-4 [14713769.001]
  • [Cites] Arch Pathol Lab Med. 1997 Oct;121(10):1081-6 [9341588.001]
  • [Cites] Hum Pathol. 1985 Jan;16(1):72-8 [3972388.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1985;48(3):207-17 [2859694.001]
  • [Cites] Recent Results Cancer Res. 2003;162:169-75 [12790331.001]
  • [Cites] Mod Pathol. 1999 Mar;12(3):310-7 [10102617.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):957-60 [11861363.001]
  • [Cites] Am J Surg Pathol. 1984 May;8(5):335-44 [6329005.001]
  • [Cites] Am J Pathol. 1994 Aug;145(2):356-64 [7519827.001]
  • [Cites] Histopathology. 1994 Sep;25(3):197-207 [7821887.001]
  • [Cites] Mod Pathol. 2002 Feb;15(2):125-36 [11850541.001]
  • [Cites] Ann Diagn Pathol. 1998 Jun;2(3):149-53 [9845733.001]
  • [Cites] Am J Surg Pathol. 1995 Nov;19(11):1245-56 [7573686.001]
  • [Cites] Am J Surg Pathol. 1999 May;23(5):530-5 [10328084.001]
  • [Cites] Am J Surg Pathol. 1990 Mar;14(3):260-7 [2305931.001]
  • [Cites] Int J Surg Pathol. 2001 Jul;9(3):215-22 [11584318.001]
  • [Cites] Leuk Res. 2001 Jul;25(7):571-6 [11377682.001]
  • [Cites] Ultrastruct Pathol. 1988 Jan-Feb;12(1):131-6 [3354071.001]
  • [Cites] Ann Diagn Pathol. 2002 Aug;6(4):244-7 [12170456.001]
  • [Cites] Diagn Cytopathol. 2000 Jan;22(1):3-6 [10613963.001]
  • [Cites] Am J Surg Pathol. 1997 Jan;21(1):1-12 [8990136.001]
  • [Cites] Am J Surg Pathol. 1989 Nov;13(11):921-30 [2679153.001]
  • [Cites] Am J Clin Pathol. 1991 May;95(5):633-7 [2024622.001]
  • [Cites] Acta Histochem. 1955 Sep 26;2(1-2):68-70 [13282671.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1188-95 [9331291.001]
  • [Cites] Hum Pathol. 2001 Feb;32(2):233-6 [11230713.001]
  • [Cites] J Pathol. 1988 Aug;155(4):277-87 [2459332.001]
  • [Cites] Pathol Res Pract. 1996 Dec;192(12):1275-81; discussion 1282 [9182300.001]
  • [Cites] Nucleic Acids Res. 1994 Jul 25;22(14):2760-8 [8052531.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):1967-72 [12057901.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):676-8 [15105658.001]
  • [Cites] Am J Clin Pathol. 1998 Dec;110(6):782-7 [9844591.001]
  • [Cites] Endocr Pathol. 1996 Winter;7(4):345-348 [12114806.001]
  • [Cites] Histopathology. 2004 Jun;44(6):542-6 [15186268.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):2081-8 [8952540.001]
  • [Cites] J Urol. 1995 Sep;154(3):964-7 [7637102.001]
  • (PMID = 15756595.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Pigments, Biological
  •  go-up   go-down


33. Demirović A, Džombeta T, Tomas D, Spajić B, Pavić I, Hudolin T, Milošević M, Cupić H, Krušlin B: Immunohistochemical expression of tumor antigens MAGE-A3/4 and NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma. Pathol Res Pract; 2010 Oct 15;206(10):695-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of tumor antigens MAGE-A3/4 and NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma.
  • The distinction between renal oncocytoma (RO) and chromophobe renal cell carcinoma (ChRCC), especially the eosinophilic variant, can often be difficult.
  • [MeSH-minor] Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / immunology. Adenoma, Oxyphilic / pathology. Aged. Aged, 80 and over. Croatia. Diagnosis, Differential. Female. Humans. Kidney Neoplasms / diagnosis. Kidney Neoplasms / immunology. Kidney Neoplasms / pathology. Male. Middle Aged. Predictive Value of Tests


34. Salido M, Lloreta J, Melero C, García M, Placer J, Espinet B, Villa O, Bielsa O, Gelabert-Mas A, Serrano S, Solé F: Insertion (8;11) in a renal oncocytoma with multifocal transformation to chromophobe renal cell carcinoma. Cancer Genet Cytogenet; 2005 Dec;163(2):160-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insertion (8;11) in a renal oncocytoma with multifocal transformation to chromophobe renal cell carcinoma.
  • We report the case of a 43-year-old male with multiple tumor foci showing microscopic features of chromophobe renal carcinoma (ChRCC) arising in an oncocytoma.
  • The multiple foci of chromophobe carcinoma presented multiple copies of CCND1, suggesting that they represented a transformation from oncocytoma into ChRCC.
  • There was immunohistochemical overexpression of CCND1 in both oncocytoma and chromophobe carcinoma cells.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Carcinoma, Renal Cell / genetics. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 8. Kidney Neoplasms / genetics


35. Delongchamps NB, Galmiche L, Eiss D, Rouach Y, Vogt B, Timsit MO, Vieillefond A, Méjean A: Hybrid tumour 'oncocytoma-chromophobe renal cell carcinoma' of the kidney: a report of seven sporadic cases. BJU Int; 2009 May;103(10):1381-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hybrid tumour 'oncocytoma-chromophobe renal cell carcinoma' of the kidney: a report of seven sporadic cases.
  • OBJECTIVES: To determine whether renal hybrid tumours (HT) appear as a specific clinical and radiological entity, as HT are characterized by the association of both oncocytes and chromophobe cells within the same tumour, and have been described in patients with oncocytosis and Birt-Hogg-Dube syndrome.
  • PATIENTS AND METHODS: We reviewed the medical charts of 67 patients who had a partial or radical nephrectomy in our institution for renal oncocytoma (RO, 24), chromophobe renal cell carcinoma (CRCC, 36) and HT (seven), from January 2006 to October 2007.
  • After a median (range) follow-up of 20 (8-25) months, none of the patients had any evidence of disease recurrence.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Nephrectomy / methods. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Female. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis


36. Kageyama K, Ikeda H, Nigawara T, Sakihara S, Suda T: Expression of adrenocorticotropic hormone, prolactin and transcriptional factors in clinically nonfunctioning pituitary adenoma. Endocr J; 2007 Dec;54(6):961-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of adrenocorticotropic hormone, prolactin and transcriptional factors in clinically nonfunctioning pituitary adenoma.
  • We describe here a case of a clinically nonfunctioning pituitary adenoma, but with expression of ACTH and PRL.
  • A 42-year-old woman was referred to our department for further evaluation of pituitary tumor.
  • Based on these findings we did not clinically suspect ACTH-producing tumor, however immunohistochemistry revealed ACTH immunoreactivity in the pituitary adenoma.
  • Therefore, the tumor was considered a silent corticotroph adenoma.
  • Ptx1, Neuro D1, and T pit were densely expressed and Pit-1 was sparsely expressed in the nuclei of adenoma cells.
  • [MeSH-major] Adenoma, Chromophobe / metabolism. Adrenocorticotropic Hormone / biosynthesis. Pituitary Neoplasms / metabolism. Prolactin / biosynthesis. Transcription Factors / biosynthesis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079591.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / ERGIC2 protein, human; 0 / Homeodomain Proteins; 0 / NEUROD1 protein, human; 0 / T-Box Domain Proteins; 0 / TBX19 protein, human; 0 / Transcription Factor Pit-1; 0 / Transcription Factors; 0 / Vesicular Transport Proteins; 12629-01-5 / Human Growth Hormone; 9002-60-2 / Adrenocorticotropic Hormone; 9002-62-4 / Prolactin; 9002-71-5 / Thyrotropin
  •  go-up   go-down


37. Memeo L, Jhang J, Assaad AM, McKiernan JM, Murty VV, Hibshoosh H, Tong GX, Mansukhani MM: Immunohistochemical analysis for cytokeratin 7, KIT, and PAX2: value in the differential diagnosis of chromophobe cell carcinoma. Am J Clin Pathol; 2007 Feb;127(2):225-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis for cytokeratin 7, KIT, and PAX2: value in the differential diagnosis of chromophobe cell carcinoma.
  • Immunohistochemical staining for cytokeratin 7 (CK7), KIT, and PAX2 expression was performed on 91 renal neoplasms, 37 conventional (clear cell) renal cell carcinomas (CRCCs), 20 papillary RCCs (PRCCs), 11 chromophobe RCCs (ChCs), and 23 oncocytomas, with available karyotypes.
  • These results identify specific staining patterns of the 4 major histologic subtypes of renal neoplasms and raise the question of a relationship between chromosome 10 loss and loss of PAX2 expression in ChC.
  • [MeSH-minor] Adenoma, Oxyphilic / chemistry. Cytogenetic Analysis. Diagnosis, Differential. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17210525.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-7; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


38. Minami I, Tateno T, Yoshimoto T, Doi M, Izumiyama H, Akashi T, Hirata Y: Subclinical Cushings disease with amelioration of metabolic comorbidities after removal of pituitary tumor. Intern Med; 2006;45(21):1231-5
MedlinePlus Health Information. consumer health - Weight Loss Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subclinical Cushings disease with amelioration of metabolic comorbidities after removal of pituitary tumor.
  • A 49-year-old woman with hypertension, obesity and impaired glucose tolerance (IGT) was admitted for evaluation of pituitary incidentaloma.
  • Although she presented no Cushingoid feature, endocrine examination of hypothalamo-pituitary-adrenal (HPA) axis showed elevated basal plasma ACTH and cortisol levels, their lack of circadian rhythm, non-suppressibility to low-dose (1 mg) dexamethasone, and responsiveness to CRH, suggesting autonomous ACTH secretion from a pituitary tumor.
  • She underwent transsphenoidal surgery, and was diagnosed as chromophobe adenoma with positive ACTH immunoreactivity.
  • Thus, her metabolic comorbidities are likely due to subclinical Cushings disease.
  • [MeSH-major] Glucose Intolerance / surgery. Hypertension / surgery. Obesity / surgery. Pituitary ACTH Hypersecretion / surgery. Pituitary Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Middle Aged. Pituitary-Adrenal System / metabolism. Pituitary-Adrenal System / surgery

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139124.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


39. Delides A, Velegrakis G, Kontogeorgos G, Karagianni E, Nakas D, Helidonis E: Familial bilateral acinic cell carcinoma of the parotid synchronous with pituitary adenoma: case report. Head Neck; 2005 Sep;27(9):825-8
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial bilateral acinic cell carcinoma of the parotid synchronous with pituitary adenoma: case report.
  • Only one case of a familial recurrence of such a neoplasm and 16 cases of bilateral tumors have been reported.
  • METHODS: History files and histologic reports of a patient with bilateral multifocal acinic cell carcinoma of the parotid and a synchronous pituitary adenoma, and of the patient's sister and his father, also treated for parotid tumours, were retrieved.
  • A pituitary tumor was a chromophobe gonotrophic adenoma.
  • CONCLUSIONS: This is the 17th case of bilateral acinic cell carcinoma of the parotid gland and the second reported case with a familial recurrence.
  • It is the first with a synchronous pituitary adenoma.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma, Acinar Cell / diagnosis. Neoplasms, Multiple Primary / diagnosis. Parotid Neoplasms / diagnosis. Pituitary Neoplasms / diagnosis
  • [MeSH-minor] Genetic Predisposition to Disease. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc.
  • (PMID = 15920750.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Morelli L, Pusiol T, Piscioli I, Larosa M, Pozzoli GL, Monica B: Concurrent occurrence of three primary neoplasms with different hystotype in the same kidney, associated with an adenoma of the omolateral adrenal gland: first case report. Int J Urol; 2006 Sep;13(9):1236-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent occurrence of three primary neoplasms with different hystotype in the same kidney, associated with an adenoma of the omolateral adrenal gland: first case report.
  • We present an unusual case of concurrent occurrence of three synchronous primary tumors in the same kidney (oncocytoma, chromophobe renal cell carcinoma, angiomyolipoma) associated to an adenoma of the omolateral adrenal gland in a patient with no evident clinical symptoms.
  • The immunohistochemistry showed a positivity for KIT in oncocytoma and chromophobe cell carcinoma, and a weak positivity in the angiomyolipoma, only in the cells positive for HMB-45.
  • [MeSH-major] Adenoma / pathology. Adenoma, Oxyphilic / pathology. Adrenal Gland Neoplasms / pathology. Angiomyolipoma / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16984560.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


41. Meyer PN, Cao Y, Jacobson K, Krausz T, Flanigan RC, Picken MM: Chromosome 1 analysis in chromophobe renal cell carcinomas with tissue microarray (TMA)-facilitated fluorescence in situ hybridization (FISH) demonstrates loss of 1p/1 which is also present in renal oncocytomas. Diagn Mol Pathol; 2008 Sep;17(3):141-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosome 1 analysis in chromophobe renal cell carcinomas with tissue microarray (TMA)-facilitated fluorescence in situ hybridization (FISH) demonstrates loss of 1p/1 which is also present in renal oncocytomas.
  • Morphologic overlap between chromophobe renal cell carcinoma (ChRCC) and renal oncocytomas (RO) has been widely recognized.
  • We previously showed by conventional cytogenetics and fluorescent in situ hybridization (FISH) that the most common chromosomal abnormality in RO is loss of chromosome 1 or 1p.
  • In this study, 95% of ChRCCs showed abnormality of chromosome 1 by FISH.
  • These results provide further evidence to support a genetic similarity between chromophobe carcinoma and oncocytoma.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Carcinoma, Renal Cell / genetics. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Kidney Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382368.001).
  • [ISSN] 1533-4066
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Wang KL, Weinrach DM, Luan C, Han M, Lin F, Teh BT, Yang XJ: Renal papillary adenoma--a putative precursor of papillary renal cell carcinoma. Hum Pathol; 2007 Feb;38(2):239-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal papillary adenoma--a putative precursor of papillary renal cell carcinoma.
  • The purpose of this study is to determine the incidence, histomorphological features, and immunohistochemical features of papillary adenoma and elucidate its potential relationship to RCC.
  • Thirty-eight (7%) nephrectomy specimens showed histologic evidence of papillary adenoma.
  • Seven papillary adenomas (18%) occurred in the setting of acquired polycystic kidney disease (APKD), 6 in clear-cell RCCs, 3 in chromophobe RCCs, 2 in end-stage kidney disease, 1 in oncocytoma, 1 in angiomyolipoma, and 1 in renal schwannoma.
  • Furthermore, papillary adenomas were more commonly found in kidneys removed for PRCC (25%, 18/71) than in kidneys harboring clear-cell RCC (1.9%, 6/318).
  • Histomorphologically, papillary adenomas were characterized by varying proportions of papillae and tubules formed by cuboidal cells with scant basophilic cytoplasm similar to those in type 1 PRCC.
  • Adenomas associated with PRCC tend to be multiple in number (61% [11/18] of cases had >2 adenomas; mean, 5).
  • In contrast, 100% of papillary adenomas arising in other conditions had less than 2 adenomas.
  • Most of the adenomas (82%, 31/38) stained strongly for AMACR in a fashion similar to that of PRCC.
  • In this study of surgical specimens, the high coincidence, multifocality, and histologic and immunohistochemical similarities between papillary adenoma and PRCC suggest that the 2 are strongly associated and may represent a continuum of 1 biologic process.
  • In contrast, adenomas associated with APKD exhibit distinct morphological and immunohistochemical features and, therefore, may have an entirely different pathogenesis.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / enzymology. Adenocarcinoma, Clear Cell / pathology. Adenoma. Adenoma, Oxyphilic / enzymology. Adenoma, Oxyphilic / pathology. Adult. Aged. Aged, 80 and over. Angiomyolipoma / enzymology. Angiomyolipoma / pathology. Disease Progression. Female. Glutathione Transferase / analysis. Humans. Immunohistochemistry. Isoenzymes / analysis. Kidney / enzymology. Kidney / pathology. Kidney Failure, Chronic / enzymology. Kidney Failure, Chronic / pathology. Male. Middle Aged. Models, Biological. Polycystic Kidney Diseases / enzymology. Polycystic Kidney Diseases / pathology. Racemases and Epimerases / analysis

  • Genetic Alliance. consumer health - Papillary renal cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056094.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase alpha; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


43. Gillett MD, Cheville JC, Karnes RJ, Lohse CM, Kwon ED, Leibovich BC, Zincke H, Blute ML: Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J Urol; 2005 Jun;173(6):1893-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among patients with renal cell carcinoma (RCC), younger patients were more likely to have chromophobe RCC (13.1% vs 3.6%) and less likely to have clear cell RCC (70.1% vs 81.5%) than older patients.
  • CONCLUSIONS: We found that patients 18 to 40 years old were more likely to have chromophobe and less likely to have clear cell RCC compared with patients 60 to 70 years old.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenoma, Chromophobe / mortality. Adenoma, Chromophobe / pathology. Adenoma, Chromophobe / surgery. Adolescent. Age Factors. Aged. Carcinoma, Renal Cell / mortality. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Diagnosis, Differential. Disease Progression. Female. Humans. Kidney / pathology. Kidney Diseases, Cystic / mortality. Kidney Diseases, Cystic / pathology. Kidney Diseases, Cystic / surgery. Male. Middle Aged. Neoplasm Staging. Sex Factors. Survival Analysis

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15879770.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Kozłowska J, Okoń K: Renal tumors in postmortem material. Pol J Pathol; 2008;59(1):21-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renal tumors include several categories, the most frequent being clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe carcinoma, oncocytoma, adenoma and angiomyolipoma.
  • The most frequent diagnosis was adenoma (53 cases, 49.1%) and, among cancers, clear cell carcinoma (20 cases, 21.1%) followed by papillary carcinoma (17 cases, 15.5%).
  • The adenomas were significantly more frequent in cases of kidneys with chronic fibrosis.
  • [MeSH-minor] Adenoma / epidemiology. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Carcinoma, Renal Cell / epidemiology. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Female. Humans. Male. Middle Aged. Poland / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18655367.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


45. Szponar A, Yusenko MV, Kovacs G: High-resolution array CGH of metanephric adenomas: lack of DNA copy number changes. Histopathology; 2010 Jan;56(2):212-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution array CGH of metanephric adenomas: lack of DNA copy number changes.
  • AIMS: Previous karyotyping and fluorescence in situ hybridization analysis of metanephric adenomas (MAs) has yielded controversial data.
  • METHODS AND RESULTS: DNA extracted from paraffin blocks of six metanephric adenomas was hybridized onto Agilent oligoarrays with approximately 43,000 in situ synthesized 60-mer oligonucleotide probes that span coding and non-coding sequences with an average spatial resolution of approximately 35 kb.
  • None of the metanephric adenomas showed DNA copy number changes.
  • To confirm our results, DNA extracted from the paraffin block of a chromophobe renal cell carcinoma (RCC) was simultaneously hybridized to one of the four arrays on the same slides as an internal control.
  • The chromophobe RCC showed loss of several chromosomes but no alteration was seen in MAs.
  • CONCLUSIONS: Our high-resolution oligoarray analysis indicates that metanephric adenomas lack DNA copy number alterations.
  • This finding may help to differentiate between metanephric adenomas from Wilms' tumour and papillary renal cell adenoma with overlapping phenotype.
  • [MeSH-major] Adenoma / genetics. DNA Copy Number Variations. Kidney Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20102400.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


46. Sengupta S, Lohse CM, Leibovich BC, Frank I, Thompson RH, Webster WS, Zincke H, Blute ML, Cheville JC, Kwon ED: Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer; 2005 Aug 1;104(3):511-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Tumor necrosis was present in 690 of 2445 (28%) clear cell, 196 of 421 (47%) papillary, and 28 of 143 (20%) chromophobe RCCs.
  • The risk ratio for death from RCC in patients with necrotic compared with non-necrotic tumors was 5.27 (95% confidence interval [CI]: 4.56-6.09; P < 0.001) for clear cell, 4.20 (CI: 1.65-10.68; P < 0.001) for chromophobe, and 1.49 (CI: 0.81-2.74; P = 0.199) for papillary RCC.
  • CONCLUSIONS: Histologic coagulative tumor necrosis is an independent predictor of outcome for clear cell and chromophobe RCC, and it should be routinely reported and used in clinical assessment.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenoma, Chromophobe / pathology. Adenoma, Chromophobe / surgery. Adult. Aged. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Female. Humans. Male. Middle Aged. Necrosis. Neoplasm Staging. Nephrectomy. Prognosis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15973740.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


47. Gołkowski F, Buziak-Bereza M, Stefańska A, Trofimiuk M, Pantofliński J, Huszno B, Czepko R, Adamek D: [A case of GH and TSH secreting pituitary macroadenoma]. Przegl Lek; 2006;63(2):106-8
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of GH and TSH secreting pituitary macroadenoma].
  • A case of GH and TSH secreting pituitary macroadenoma is reported.
  • NMR pituitary imaging revealed intra and extrasellar tumor.
  • Histological and immunohistochemical examination of the tissue obtained at transsphenoidal surgery showed GH and TSH secreting adenoma.
  • The very low plasma levels of TSH and free thyroid hormones after surgery and immunohistochemical examination suggest central hyperthyroidism due to TSH secreting pituitary tumor (thyrotropinoma).
  • [MeSH-major] Adenoma, Chromophobe / secretion. Adenoma, Chromophobe / surgery. Growth Hormone / secretion. Pituitary Neoplasms / secretion. Pituitary Neoplasms / surgery. Thyrotropin / secretion
  • [MeSH-minor] Acromegaly / diagnosis. Acromegaly / etiology. Acromegaly / surgery. Female. Humans. Hyperthyroidism / blood. Hyperthyroidism / etiology. Middle Aged. Pituitary Gland / pathology. Pituitary Gland / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967720.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin; 9002-72-6 / Growth Hormone
  •  go-up   go-down


48. Johnson NB, Johnson MM, Selig MK, Nielsen GP: Use of electron microscopy in core biopsy diagnosis of oncocytic renal tumors. Ultrastruct Pathol; 2010 Aug;34(4):189-94
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The distinction between oncocytoma and chromophobe renal cell carcinoma, important clinically, may be challenging, especially as the tissue sample size decreases.
  • The aim of this study was to examine the value of electron microscopy in differentiating between oncocytoma and chromophobe renal cell carcinoma on formalin fixed paraffin embedded needle core biopsies.
  • [MeSH-major] Adenoma, Oxyphilic / ultrastructure. Kidney Neoplasms / ultrastructure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20594037.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


49. Valladares Ayerbes M, Aparicio Gallego G, Díaz Prado S, Jiménez Fonseca P, García Campelo R, Antón Aparicio LM: Origin of renal cell carcinomas. Clin Transl Oncol; 2008 Nov;10(11):697-712
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, Knudson postulated that patients with the familial form of the cancer would be born with one mutant allele and that all cells in that organ or tissue would be at risk, accounting for early onset and the multifocal nature of the disease.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adenoma, Chromophobe / genetics. Adenoma, Chromophobe / pathology. Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / pathology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cell Lineage. Cell Transdifferentiation. Genes, Tumor Suppressor. Hematopoietic Stem Cells / pathology. Humans. Kidney Glomerulus / pathology. Mutation. Neoplasm Proteins / genetics. Neoplasm Proteins / physiology. Oncogenes

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19015066.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 94
  •  go-up   go-down


50. Tickoo SK, Gopalan A: Pathologic features of renal cortical tumors. Urol Clin North Am; 2008 Nov;35(4):551-61; v
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our better understanding of the morphologic spectrum of renal cortical tumors has resulted in a clinically more relevant classification of these tumor types.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Papillary / genetics. Adenocarcinoma, Papillary / pathology. Adenoma, Chromophobe / genetics. Adenoma, Chromophobe / pathology. Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / pathology. Carcinoma, Medullary / genetics. Carcinoma, Medullary / pathology. Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / pathology. Genetic Predisposition to Disease. Humans. Kidney Diseases, Cystic / pathology. Kidney Tubules, Collecting / pathology. Neoplasm Staging / methods. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18992609.001).
  • [ISSN] 0094-0143
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 88
  •  go-up   go-down


51. Chung TT, Evanson J, Walker D, Akker SA, Besser GM, Monson JP, Grossman AB, Drake WM: Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours. Clin Endocrinol (Oxf); 2008 Jun;68(6):965-9
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours.
  • BACKGROUND: Published data suggest that growth hormone replacement (GHR) may be given safely to patients with hypopituitarism consequent upon a pituitary/peripituitary tumour.
  • However, a preponderance of patients treated with external pituitary irradiation were included.
  • OBJECTIVE: To assess the safety of GHR in nonirradiated pituitary/peripituitary tumour.
  • PATIENTS: We imaged prospectively the pituitary glands of 48 patients (18 males; mean age 51.6 years range 21-77) who had adult onset growth hormone deficiency (AO-GHD) after appropriate treatment for a pituitary/peripituitary tumour but who did not receive external pituitary irradiation.
  • Pituitary surveillance imaging was performed prior to the commencement of GHR, at 6-12 months and then yearly.
  • Three patients were judged to have an apparent increase in tumour volume and/or marker, although only one was thought to be possibly GH related--a patient with a cystic chromophobe adenoma who demonstrated a marginal increase in residual tumour volume 4 years after commencement of GHR.
  • CONCLUSION: These data add to the growing body of evidence for the safety of GHR in hypopituitary patients consequent upon pituitary/peripituitary mass lesions and represents the first reported series in a heterogeneous group of nonirradiated patients.
  • [MeSH-major] Human Growth Hormone / adverse effects. Human Growth Hormone / therapeutic use. Hypopituitarism / drug therapy. Pituitary Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18031317.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


52. Li G, Cottier M, Sabido O, Gentil-Perret A, Lambert C, Genin C, Tostain J: Different DNA ploidy patterns for the differentiation of common subtypes of renal tumors. Cell Oncol; 2005;27(1):51-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The common subtypes of renal tumors are conventional or clear cell carcinoma, papillary carcinoma, chromophobe carcinoma and oncocytoma.
  • METHODS: 38 renal tumor samples (13 clear cell RCCs, 12 papillary RCCs, 7 chromophobe RCCs, and 6 oncocytomas) were studied.
  • Flow cytometric analysis of oncocytomas showed the diploid pattern (29/30 frequencies) while the chromophobe RCC never showed the diploid pattern (0/55 frequencies) (p<0.01).
  • 6/7 chromophobe RCCs had multiple aneuploid stemlines.
  • CONCLUSIONS: Flow cytometric analysis reveals that conventional and papillary RCCs are more homogeneous than chromophobe RCC.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenoma, Chromophobe / genetics. Adenoma, Oxyphilic / genetics. Biopsy. Carcinoma, Papillary / genetics. Cell Differentiation. Chromosome Aberrations. DNA, Neoplasm / analysis. Flow Cytometry / methods. Humans. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15750207.001).
  • [ISSN] 1570-5870
  • [Journal-full-title] Cellular oncology : the official journal of the International Society for Cellular Oncology
  • [ISO-abbreviation] Cell. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC4611118
  •  go-up   go-down


53. Li G, Gentil-Perret A, Lambert C, Genin C, Tostain J: S100A1 and KIT gene expressions in common subtypes of renal tumours. Eur J Surg Oncol; 2005 Apr;31(3):299-303
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Fifty-five tissue samples (15 clear cell RCCs, 15 papillary RCCs, 7 chromophobe RCCs, 8 oncocytomas and 10 normal renal tissues) were studied The gene expressions of S100A1 and KIT were analysed by one-step RT-PCR by using the specific primers.
  • RESULTS: S100A1 was expressed in 2/15 clear cell RCCs, 11/15 papillary RCCs, 7/8 oncocytomas and in 0/7 chromophobe RCCs.
  • KIT gene was expressed in 6/7 chromophobe RCCs and 7/8 oncocytomas while 0/15 clear cell RCCs and 1/15 papillary RCCs expressed kit gene.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / chemistry. Adenoma, Oxyphilic / chemistry. Carcinoma, Papillary / chemistry. Carcinoma, Renal Cell / chemistry. Cell Line, Tumor. Humans. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15780567.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins; 146909-89-9 / S100A11 protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


54. Breda A, Treat EG, Haft-Candell L, Leppert JT, Harper JD, Said J, Raman S, Smith RB, Belldegrun AS, Schulam PG: Comparison of accuracy of 14-, 18- and 20-G needles in ex-vivo renal mass biopsy: a prospective, blinded study. BJU Int; 2010 Apr;105(7):940-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The final pathological evaluation classified 21 masses (68%) as clear cell renal cell carcinoma (RCC), three (10%) as papillary RCC, three (10%) as chromophobe RCC, three (10%) as oncocytoma and one (3%) as a benign lymphoid infiltrate.
  • In two cases chromophobe RCC was misdiagnosed with oncocytoma, and vice versa.
  • Clear cell and papillary RCCs were accurately diagnosed on biopsy using an 18-G, whereas oncocytoma and chromophobe RCC were difficult to differentiate using standard H&E techniques and immunohistochemistry.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Biopsy, Needle / standards. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Nephrectomy / methods

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19888984.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


55. Mazal PR, Stichenwirth M, Koller A, Blach S, Haitel A, Susani M: Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study. Mod Pathol; 2005 Apr;18(4):535-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemistry for aquaporin-1, aquaporin-2, PAX-2, CD10, and cytokeratin 7 was performed on 102 clear cell renal cell carcinomas, 44 papillary renal cell carcinomas (among them 34 type 1 and 10 type 2), 24 chromophobe renal cell carcinomas, three collecting duct carcinomas (carcinomas of the collecting ducts of Bellini), and 29 oncocytomas.
  • Aquaporin-1 expression was found in clear cell renal cell carcinomas and papillary renal cell carcinomas of both types (78 and 73%, respectively), but not in chromophobe renal cell carcinomas, collecting duct carcinomas, and oncocytomas.
  • PAX-2 and CD10 was found in the majority of clear cell renal cell carcinomas (88 and 85%, respectively) but only in few papillary renal cell carcinomas, chromophobe renal cell carcinomas and oncocytomas.
  • Cytokeratin 7 was rarely seen in clear cell renal cell carcinomas, type 2 papillary renal cell carcinomas, and oncocytomas, but was found in the majority of type 1 papillary renal cell carcinomas (97.1%) and chromophobe renal cell carcinomas (88%).
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Aquaporin 1. Aquaporin 2. Aquaporins / biosynthesis. Blood Group Antigens. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. DNA-Binding Proteins / biosynthesis. Humans. Immunohistochemistry. Keratin-7. Keratins / biosynthesis. Kidney / chemistry. Kidney / pathology. Neoplasm Staging. Neprilysin / biosynthesis. PAX2 Transcription Factor. Tissue Array Analysis / methods. Transcription Factors / biosynthesis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15502805.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AQP1 protein, human; 0 / AQP2 protein, human; 0 / Aquaporin 2; 0 / Aquaporins; 0 / Biomarkers, Tumor; 0 / Blood Group Antigens; 0 / DNA-Binding Proteins; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; 0 / Transcription Factors; 146410-94-8 / Aquaporin 1; 68238-35-7 / Keratins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


56. Németh I, Sükösd F, Béli L, Kiss A, Pajor L, Mikó T, Iványi B: [Adult renal neoplasms in the material of the Pathology Department of the Szeged University]. Orv Hetil; 2005 Apr 3;146(14):653-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 88.4% of the renal cell carcinomas (n = 328) were of conventional type, 5.6% (n = 21) were papillary and 4% (n = 15) were chromophobe.
  • The median age of the patients with conventional carcinoma was 60 (median, range: 25-84), in the papillary group it was 62 (43-78), and in the chromophobe group was 59 (17-77).
  • [MeSH-minor] Adenocarcinoma, Clear Cell / epidemiology. Adenocarcinoma, Clear Cell / pathology. Adenoma, Chromophobe / epidemiology. Adenoma, Chromophobe / pathology. Adenoma, Oxyphilic / epidemiology. Adenoma, Oxyphilic / pathology. Adult. Aged. Angiomyolipoma / epidemiology. Angiomyolipoma / pathology. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / epidemiology. Carcinoma, Renal Cell / pathology. Carcinoma, Transitional Cell / epidemiology. Carcinoma, Transitional Cell / pathology. Female. Humans. Hungary / epidemiology. Male. Middle Aged. Nephrectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15889540.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


57. Liu W, Tretiakova M, Kong J, Turkyilmaz M, Li YC, Krausz T: Expression of vitamin D3 receptor in kidney tumors. Hum Pathol; 2006 Oct;37(10):1268-78
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Paraffin tissue microarray (TMA) blocks were constructed containing core cylinders from clear cell (52), papillary (35), chromophobe (20), sarcomatoid (20), and metastatic (59) renal cell carcinomas (RCCs).
  • Vitamin D receptor was strongly positive in collecting duct carcinomas (100% [3/3], cytoplasmic), papillary RCCs (94% [33/35], cytoplasmic), chromophobe RCCs (85% [17/20], membranous), and oncocytomas (90% [18/20], cytoplasmic with perinuclear accentuation).
  • The preferential expression of VDR in chromophobe RCCs, oncocytomas, and collecting duct carcinomas is in agreement with the concept that these tumors differentiate toward epithelium lining the distal convoluted tubules and collecting ducts.
  • Considering the different VDR expression patterns, VDR is a useful ancillary tool in distinguishing chromophobe RCCs from oncocytomas.
  • [MeSH-major] Adenoma, Oxyphilic / metabolism. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism. Receptors, Calcitriol / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949927.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Calcitriol
  •  go-up   go-down


58. Alroy J, Ucci AA, Azabdoaftari G, Banner BF, Cheville JC: Expression of CD3 antigens in renal tubule epithelium and renal oncocytomas. Pathol Res Pract; 2005;201(12):803-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD3 expression was strong in normal proximal and distal tubular epithelium in most species and in renal oncocytomas, weak in chromophobe carcinoma, and negative in clear cell carcinomas, in papillary renal cell carcinoma, and in a transitional cell carcinoma.
  • [MeSH-major] Adenoma, Oxyphilic / metabolism. Antigens, CD3 / metabolism. Kidney Neoplasms / metabolism. Kidney Tubules / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16308105.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD3
  •  go-up   go-down


59. Nagashima Y, Mitsuya T, Shioi KI, Noguchi S, Kishida T, Hamano A, Ohgo Y, Tsuura Y, Ogawa T, Aoki I, Yao M: Renal oncocytosis. Pathol Int; 2005 Apr;55(4):210-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the rare occurrence pathologists and urologists should be aware of renal oncocytosis, as a precursor lesion of renal oncocytoma and chromophobe renal cell carcinoma.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Kidney / pathology. Kidney Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15826248.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Cadherins; 0 / FLCN protein, human; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / Mucin-1; 0 / Proteins; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins; 0 / Vimentin; 68238-35-7 / Keratins
  • [Number-of-references] 21
  •  go-up   go-down


60. Brunotte I, Haubitz B, Winter R, Meyer MW: [Differential diagnosis in visual field defects of glaucoma patients]. Klin Monbl Augenheilkd; 2008 Feb;225(2):169-72
MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recommend the performance of a radiological examination in patients with visual field defects if the intraocular pressure is normal and thus glaucoma may not be the cause of the defects.
  • [MeSH-major] Adenoma, Chromophobe / diagnosis. Glaucoma / diagnosis. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Optic Nerve Diseases / diagnosis. Pituitary Neoplasms / diagnosis. Vision Disorders / diagnosis. Visual Fields


61. Adley BP, Schafernak KT, Yeldandi AV, Yang XJ, Nayar R: Cytologic and histologic findings in multiple renal hybrid oncocytic tumors in a patient with Birt-Hogg-Dubé syndrome: a case report. Acta Cytol; 2006 Sep-Oct;50(5):584-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A variety of histologic types of renal tumors have been reported, including clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC, oncocytoma and a recently described hybrid oncocytic tumor, which is thought to be highly associated with BHD.
  • CASE: We report a case of a 48-year-old woman with BHD who initially presented to our institution with spontaneous pneumothorax and was found to have multiple lung cysts and renal tumors on computed tomography.
  • [MeSH-major] Adenoma, Oxyphilic / radiography. Cysts / radiography. Kidney / radiography. Kidney Neoplasms / radiography. Lung Neoplasms / radiography. Neoplasms, Multiple Primary / radiography


62. Alshumrani G, O'Malley M, Ghai S, Metser U, Kachura J, Finelli A, Mattar K, Panzarella T: Small (&lt; or = 4 cm) cortical renal tumors: characterization with multidetector CT. Abdom Imaging; 2010 Aug;35(4):488-93
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two radiologists reviewed CT studies blinded to pathology results and recorded the morphologic and enhancement features of the tumors.
  • RESULTS: The 47 tumors (median diameter, 2.5 cm; range, 0.6-4.0 cm) included: 26 (55%) clear cell renal cell carcinomas; 9 (19%) oncocytomas; 7 (15%) papillary renal cell carcinomas; 2 (4%) chromophobe renal cell carcinomas; 2 (4%) inflammatory pseudotumors; and 1 (2%) angiomyolipoma with minimal fat.
  • [MeSH-minor] Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / radiography. Adult. Aged. Aged, 80 and over. Angiomyolipoma / pathology. Angiomyolipoma / radiography. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / radiography. Female. Granuloma, Plasma Cell / pathology. Granuloma, Plasma Cell / radiography. Humans. Kidney Diseases / pathology. Kidney Diseases / radiography. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19536589.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Kato N, Honma K, Hojo H, Sasou S, Matsuzaki O, Motoyama T: KIT expression in normal and neoplastic renal tissues: immunohistochemical and molecular genetic analysis. Pathol Int; 2005 Aug;55(8):479-83
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renal chromophobe cell carcinomas (ChCC) and oncocytomas express KIT.
  • [MeSH-minor] Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Angiomyolipoma / genetics. Angiomyolipoma / metabolism. Angiomyolipoma / pathology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. DNA Mutational Analysis. Gene Expression. Humans. Immunohistochemistry. Kidney Tubules, Collecting / chemistry. Kidney Tubules, Collecting / metabolism. Kidney Tubules, Collecting / pathology. Nephroma, Mesoblastic / genetics. Nephroma, Mesoblastic / metabolism. Nephroma, Mesoblastic / pathology. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Receptor, Platelet-Derived Growth Factor alpha / biosynthesis. Receptor, Platelet-Derived Growth Factor alpha / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15998375.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


64. Klomp JA, Petillo D, Niemi NM, Dykema KJ, Chen J, Yang XJ, Sääf A, Zickert P, Aly M, Bergerheim U, Nordenskjöld M, Gad S, Giraud S, Denoux Y, Yonneau L, Méjean A, Vasiliu V, Richard S, MacKeigan JP, Teh BT, Furge KA: Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression. BMC Med Genomics; 2010;3:59
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Germline mutations in the folliculin (FLCN) gene are associated with the development of Birt-Hogg-Dubé syndrome (BHDS), a disease characterized by papular skin lesions, a high occurrence of spontaneous pneumothorax, and the development of renal neoplasias.
  • The majority of renal tumors that arise in BHDS-affected individuals are histologically similar to sporadic chromophobe renal cell carcinoma (RCC) and sporadic renal oncocytoma.
  • RESULTS: Renal tumors isolated from individuals with BHDS showed distinct gene expression and cytogenetic characteristics from sporadic renal oncocytoma and chromophobe RCC.
  • [MeSH-minor] Adenoma, Oxyphilic / genetics. Carcinoma, Renal Cell / genetics. DNA-Binding Proteins / metabolism. Estrone / genetics. Heat-Shock Proteins / genetics. Heat-Shock Proteins / metabolism. Humans. Mitochondrial Proteins / metabolism. Oxidative Phosphorylation. Signal Transduction. Transcription Factors / genetics. Transcription Factors / metabolism

  • Genetic Alliance. consumer health - Birt-Hogg-Dube Syndrome.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2005 Dec;96(9):1275-9 [16287444.001]
  • [Cites] PLoS One. 2008;3(10):e3581 [18974783.001]
  • [Cites] Am J Surg Pathol. 2008 Dec;32(12):1822-34 [18813125.001]
  • [Cites] Oncogene. 2009 Apr 2;28(13):1594-604 [19234517.001]
  • [Cites] Cancer Res. 2009 Jun 1;69(11):4674-81 [19470766.001]
  • [Cites] Annu Rev Physiol. 2009;71:177-203 [19575678.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8256-64 [19843858.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18722-7 [19850877.001]
  • [Cites] Lancet Oncol. 2009 Dec;10(12):1199-206 [19959076.001]
  • [Cites] Int J Biol Sci. 2010;6(3):213-24 [20440404.001]
  • [Cites] Int J Urol. 2010 Jul;17(7):592-600 [20590942.001]
  • [Cites] Int J Urol. 2010 Jul;17(7):602-12 [20590944.001]
  • [Cites] Oncogene. 2006 May 11;25(20):2885-9 [16369488.001]
  • [Cites] Bioinformatics. 2006 Jun 15;22(12):1540-2 [16595560.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6087-96 [16778181.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15552-7 [17028174.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jan;46(1):75-86 [17044051.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):6937-45 [17145811.001]
  • [Cites] Arch Pathol Lab Med. 2006 Dec;130(12):1865-70 [17149965.001]
  • [Cites] Mol Cell. 2006 Dec 8;24(5):797-803 [17157261.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jan;131(1):81-5 [17227127.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):336-40 [17133269.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):671s-679s [17255292.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):680s-684s [17255293.001]
  • [Cites] Oncogene. 2007 Feb 26;26(9):1346-50 [17322920.001]
  • [Cites] J Pathol. 2007 Apr;211(5):524-31 [17323425.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3171-6 [17409424.001]
  • [Cites] Hum Mol Genet. 2007 Apr 15;16(8):993-1005 [17341490.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):736-40 [18046414.001]
  • [Cites] J Natl Cancer Inst. 2008 Jan 16;100(2):140-54 [18182616.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Jan 15;180(2):100-9 [18206534.001]
  • [Cites] Hum Mol Genet. 2008 Apr 1;17(7):986-95 [18156159.001]
  • [Cites] Physiol Rev. 2008 Apr;88(2):611-38 [18391175.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2270-5 [18413815.001]
  • [Cites] Gene. 2008 May 31;415(1-2):60-7 [18403135.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4034-8 [18519660.001]
  • [Cites] J Med Genet. 2008 Jun;45(6):321-31 [18234728.001]
  • [Cites] Cardiovasc Res. 2008 Jul 15;79(2):208-17 [18430751.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4726-34 [18676741.001]
  • [Cites] PLoS Genet. 2008;4(9):e1000176 [18773095.001]
  • [Cites] Oncogene. 2008 Sep 11;27(40):5339-47 [18663353.001]
  • [Cites] Mod Pathol. 2001 Aug;14(8):760-7 [11504835.001]
  • [Cites] Eur Urol. 2001 Sep;40(3):330-6 [11684851.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):157-64 [12204536.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1542-52 [12459621.001]
  • [Cites] J Med Genet. 2002 Dec;39(12):906-12 [12471204.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):925-32 [12598325.001]
  • [Cites] Nat Genet. 2003 Jul;34(3):267-73 [12808457.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4583-7 [12907635.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 24;310(3):779-84 [14550271.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6810-8 [14555994.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Bioinformatics. 2004 Oct 12;20(15):2471-2 [15073005.001]
  • [Cites] Genes Chromosomes Cancer. 1989 Sep;1(1):79-82 [2487148.001]
  • [Cites] J Pathol. 1992 Jul;167(3):273-7 [1381433.001]
  • [Cites] Histopathology. 1993 Jan;22(1):1-8 [8436337.001]
  • [Cites] J Biol Chem. 1993 Jun 5;268(16):12156-63 [8505336.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jul 15;96(2):95-101 [9216713.001]
  • [Cites] J Mol Diagn. 2005 May;7(2):206-18 [15858144.001]
  • [Cites] BMC Genomics. 2005;6:67 [15882461.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):931-5 [15956655.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5628-37 [15994935.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] J Cell Physiol. 2006 Jan;206(1):103-11 [15920738.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e175 [16284200.001]
  • (PMID = 21162720.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Heat-Shock Proteins; 0 / Mitochondrial Proteins; 0 / PPARGC1A protein, human; 0 / TFAM protein, human; 0 / Transcription Factors; 2DI9HA706A / Estrone; Oncocytoma, renal
  • [Other-IDs] NLM/ PMC3012009
  •  go-up   go-down


65. Ruggeri RM, Santarpia L, Curtò L, Torre ML, Galatioto M, Galatioto S, Trimarchi F, Cannavò S: Non-functioning pituitary adenomas infrequently harbor G-protein gene mutations. J Endocrinol Invest; 2008 Nov;31(11):946-9
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-functioning pituitary adenomas infrequently harbor G-protein gene mutations.
  • BACKGROUND: Mutations of the genes encoding the alpha subunit of the stimulatory G protein (Gs) and of the inhibiting Gi2 protein (GNAS1 and GNAI2 genes, respectively) have been described in various endocrine neoplasias, including pituitary tumors.
  • AIM: To search for mutations of GNAS1 and GNAI2 in a continuous series of non-functioning pituitary adenoma (NFPA) patients neurosurgically treated.
  • CONCLUSIONS: This finding suggests and confirms that G-protein mutations are rare and not crucial in NFPA development.
  • [MeSH-major] Adenoma, Acidophil / genetics. Adenoma, Chromophobe / genetics. GTP-Binding Protein alpha Subunits, Gs / genetics. Intracellular Signaling Peptides and Proteins / genetics. Pituitary Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169048.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Codon; 0 / Intracellular Signaling Peptides and Proteins; 0 / URI1 protein, human; EC 3.6.1.- / GNAS protein, human; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
  •  go-up   go-down


66. Chen YT, Tu JJ, Kao J, Zhou XK, Mazumdar M: Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma. Clin Cancer Res; 2005 Sep 15;11(18):6558-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Morphologic distinction among clear cell, papillary, and chromophobe types of renal cell carcinoma (RCC) can be difficult, as is the differential diagnosis between oncocytoma and RCC.
  • Whether these renal tumors can be distinguished by their mRNA expression profile of a few selected genes was examined.
  • RESULTS: CA9 expression was highest in clear cell carcinoma and lowest in chromophobe RCC and in oncocytoma.
  • AMACR expression was highest in papillary RCC, and CLCNKB was highest in chromophobe RCC/oncocytoma.
  • PVALB was highest in chromophobe RCC, variable in oncocytoma, and low in clear cell and papillary types.
  • This algorithm accurately classified the 31 fresh-frozen tumors into 14 clear cell, 5 papillary, 6 chromophobe, and 6 oncocytomas.
  • In the formalin-fixed group, the molecular criteria accurately classified the cases into 15 clear cell, 16 papillary, and 32 in the chromophobe/oncocytoma group but could only separate some, but not all, oncocytomas from chromophobe RCC.
  • CONCLUSIONS: RNA expression ratios based on the four-gene panel can accurately classify subtypes of RCC as well as help distinguish some oncocytomas from chromophobe RCC.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / pathology. Algorithms. Anion Transport Proteins / genetics. Antigens, Neoplasm / genetics. Carbonic Anhydrases / genetics. Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / pathology. Chloride Channels / genetics. Diagnosis, Differential. Humans. Membrane Proteins / genetics. Racemases and Epimerases / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. beta-Defensins / genetics

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166433.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anion Transport Proteins; 0 / Antigens, Neoplasm; 0 / CLCNKB protein, human; 0 / Chloride Channels; 0 / DEFB1 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / beta-Defensins; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


67. Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ, Teh BT: MicroRNA profiling of human kidney cancer subtypes. Int J Oncol; 2009 Jul;35(1):109-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to understand their role in renal tumorigenesis, we screened the expression levels of miRNAs in four subtypes of human renal neoplasms: clear cell, papillary, and chromophobe renal cell carcinomas (RCC) as well as benign renal oncocytomas.
  • Specifically, we documented the overexpression of miRs 424 and 203 in clear cell RCC relative to papillary RCC, as well as the inversion of expression of miR-203 in the benign oncocytomas (where it is underexpressed relative to normal kidney) as compared to the malignant chromophobe RCC (where it is overexpressed relative to normal kidney).
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Carcinoma, Renal Cell / genetics. Gene Expression Profiling / methods. Kidney Neoplasms / genetics. MicroRNAs / analysis

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19513557.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


68. Dong YC, Wu B, Wang JD, Rao Q, Ma HH, Zhang RS, Zhou HB, Lu ZF, Zhou XJ: [Expression and clinical significance of kidney injury molecule-1 in renal epithelial neoplasms]. Zhonghua Bing Li Xue Za Zhi; 2010 Jan;39(1):35-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 136 cases of kidney neoplasms were retrospectively reviewed including 63 primary clear cell renal cell carcinomas (RCCs), 22 papillary RCCs, 13 chromophobe RCCs, 7 oncocytomas, 7 RCCs associated with Xp11.2 translocation/TFE3 gene fusions and 24 metastatic clear cell RCCs.
  • RESULTS: Expression of KIM-1 was detected in 77.8% (49/63) of clear cell RCCs, 90.9% (20/22) of papillary RCCs, 1/13 of chromophobe RCCs, 7/7 of RCCs associated with Xp11.2 translocation/TFE3 gene fusions and 87.5%(21/24) of the metastatic RCCs, but not detected in 7 cases of oncocytomas.
  • Ksp-cadherin expression was mainly observed in chromophobe RCCs and oncocytomas.
  • [MeSH-minor] Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / genetics. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / metabolism. Bone Neoplasms / metabolism. Bone Neoplasms / secondary. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Chromosomes, Human, X. Gene Fusion. Humans. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Retrospective Studies. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20388397.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / CDH16 protein, human; 0 / Cadherins; 0 / HAVCR1 protein, human; 0 / Membrane Glycoproteins; 0 / Receptors, Virus; 0 / TFE3 protein, human
  •  go-up   go-down


69. Blandamura S, Giacomelli L, Leo G, Segato P, Ninfo V: Nuclear maspin detection in renal cell tumours: possible diagnostic role and correlation with p53 status. Histopathology; 2006 Sep;49(3):274-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All clear cell carcinomas (CC) were negative for maspin, whereas oncocytomas (OC), papillary renal cell carcinomas (PC), chromophobe carcinomas (CPC) and, at least focally, collecting duct carcinomas (CDC) stained positively.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Serpins / biosynthesis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16918974.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SERPIN-B5; 0 / Serpins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


70. Cossu-Rocca P, Eble JN, Zhang S, Bonsib SM, Martignoni G, Brunelli M, Cheng L: Interphase cytogenetic analysis with centromeric probes for chromosomes 1, 2, 6, 10, and 17 in 11 tumors from a patient with bilateral renal oncocytosis. Mod Pathol; 2008 Apr;21(4):498-504
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The morphologic features of the oncocytic nodules encompass a spectrum of appearances, with patterns typical of renal oncocytoma or classic chromophobe renal cell carcinoma, as well as 'hybrid' tumors with features resembling both oncocytoma and chromophobe renal cell carcinoma.
  • We utilized interphase cytogenetic methods to study 11 tumors from the kidneys of a 45-year-old woman.
  • The tumors included morphologically classical oncocytomas and 'hybrid' tumors with features reminiscent of chromophobe carcinoma.
  • Fluorescence in situ hybridization was performed with centromeric probes for chromosomes 1, 2, 6, 10, and 17 in each of the 11 tumors to determine whether or not there were losses of the chromosomes that are most frequently lost in chromophobe renal cell carcinomas.
  • These observations weigh against the concept that hybrid tumors of oncocytosis are closely related to chromophobe renal cell carcinoma.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / pathology. Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / genetics. Kidney Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246052.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Shen SS, Krishna B, Chirala R, Amato RJ, Truong LD: Kidney-specific cadherin, a specific marker for the distal portion of the nephron and related renal neoplasms. Mod Pathol; 2005 Jul;18(7):933-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clear cell and papillary renal cell carcinoma (RCC) are thought to be of proximal tubular origin, whereas oncocytoma and chromophobe RCC are derived from intercalated cells of distal nephron.
  • The expression of kidney-specific (Ksp) cadherin, a recently cloned gene thought to be transcribed exclusively in the kidney, was studied in normal human kidney, as well as in 105 primary renal neoplasms, including 42 clear cell RCC, 30 papillary RCC, 13 chromophobe RCC, and 20 oncocytomas.
  • All 13 chromophobe RCC and 19 of 20 oncocytomas showed diffuse and strong immunoreactivity for Ksp-cadherin, while only 14% clear cell RCC and 13% papillary RCC showed focal positivity.
  • The RCC marker expression was detected in 85%, 98%, 15% and 0% of clear cell RCC, papillary RCC, chromophobe RCC, and oncocytoma, respectively.
  • These results demonstrated high sensitivity and specificity of Ksp-cadherin for distal convoluted tubules, which can be used as adjunct for diagnosis of chromophobe RCC.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Biomarkers / analysis. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Kidney Tubules / chemistry

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696118.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cadherins; 0 / FAT1 protein, human
  •  go-up   go-down


72. Vieira J, Henrique R, Ribeiro FR, Barros-Silva JD, Peixoto A, Santos C, Pinheiro M, Costa VL, Soares MJ, Oliveira J, Jerónimo C, Teixeira MR: Feasibility of differential diagnosis of kidney tumors by comparative genomic hybridization of fine needle aspiration biopsies. Genes Chromosomes Cancer; 2010 Oct;49(10):935-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The association of a genetic analysis that could improve the diagnostic accuracy of renal cell tumors in biopsy samples would allow better-informed therapeutic decisions.
  • The genetic pattern correctly diagnosed 93.5% of clear cell renal cell carcinomas (RCC), 61.5% of chromophobe RCC, 100% of papillary RCC, and 14.3% of oncocytomas, with the negative predictive value being 93.9, 90.7, 100, and 90.2%, respectively.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Carcinoma, Renal Cell / diagnosis. Chromosomes, Human / genetics. Comparative Genomic Hybridization. Kidney Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629095.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


73. Qiao MZ, Li CL: [Nephron-sparing surgery for 69 patients with renal tumors]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun;28(3):335-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histological subtypes included clear cell carcinoma in 40 cases, papillary renal cell carcinoma (RCC) in 2 cases, chromophobe RCC in 2 cases, angiomyolipoma in 24 cases, and adenoma in one case.
  • The overall and disease-free 5-year survival rates were 97.3% and 90.7%, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16900628.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


74. Arias LF, Bruneval P, Blanco J: Renin expression in adult renal epithelial tumors with granular cells. Pathol Res Pract; 2010 Nov 15;206(11):731-4
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renin was detected in 31.6% of 38 chromophobe carcinomas and in 12.5% of 24 conventional carcinomas.
  • [MeSH-minor] Adenoma, Oxyphilic / complications. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cytoplasm / metabolism. Cytoplasm / pathology. Cytoplasmic Granules / metabolism. Female. Humans. Hypertension / complications. Immunoenzyme Techniques. Kidney / metabolism. Kidney / surgery. Kidney Tubules, Collecting / metabolism. Kidney Tubules, Collecting / pathology. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20619546.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.23.15 / Renin; Oncocytoma, renal
  •  go-up   go-down


75. Dvorakova M, Dhir R, Bastacky SI, Cieply KM, Acquafondata MB, Sherer CR, Mercuri TL, Parwani AV: Renal oncocytoma: a comparative clinicopathologic study and fluorescent in-situ hybridization analysis of 73 cases with long-term follow-up. Diagn Pathol; 2010;5:32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In diagnostically challenging cases of renal oncocytic epithelial neoplasms, fluorescent in-situ hybridization (FISH) is increasingly being used and its ability to distinguish RO from chromophobe renal cell carcinoma (ChRCC) has been documented.
  • A total of 18% cases did not show any abnormality.Our study shows that chromosomal abnormalities in both ROs and ChRCCs are common with frequent loss of chromosomes 1 and 17.
  • [MeSH-minor] Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / mortality. Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / surgery. Adult. Aged. Aged, 80 and over. Chromosomes, Human, Pair 2. Female. Fixatives. Follow-Up Studies. Formaldehyde. Humans. Kidney Neoplasms / genetics. Kidney Neoplasms / mortality. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Male. Middle Aged. Nephrectomy. Paraffin Embedding. Predictive Value of Tests. Time Factors. Tissue Fixation. Treatment Outcome

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 2005 Jul 15;160(2):120-5 [15993267.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6558-66 [16166433.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jan;131(1):81-5 [17227127.001]
  • [Cites] J Clin Pathol. 2007 Jun;60(6):585-6 [17557864.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):871-83 [9255250.001]
  • [Cites] Diagn Cytopathol. 2000 Jan;22(1):3-6 [10613963.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1247-56 [10976699.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):275-84 [11224597.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1639-51 [11337362.001]
  • [Cites] Am J Hum Genet. 2001 Oct;69(4):876-82 [11533913.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):281-91 [11859199.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):157-64 [12204536.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1542-52 [12459621.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):1053-9 [14559990.001]
  • [Cites] J Med Genet. 2003 Nov;40(11):820-4 [14627671.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2163-72 [14634372.001]
  • [Cites] Int J Cancer. 1993 Sep 9;55(2):223-7 [8370620.001]
  • [Cites] Am J Pathol. 1994 Aug;145(2):356-64 [7519827.001]
  • [Cites] J Urol. 1996 Jul;156(1):31-5 [8648831.001]
  • [Cites] Genes Chromosomes Cancer. 1996 May;16(1):64-7 [9162199.001]
  • [Cites] Diagn Mol Pathol. 1996 Mar;5(1):53-64 [8919546.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Nov;92(1):28-30 [8956867.001]
  • [Cites] Am J Surg Pathol. 1997 Jan;21(1):1-12 [8990136.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1188-95 [9331291.001]
  • [Cites] Int J Cancer. 1997 Nov 14;73(4):521-4 [9389566.001]
  • [Cites] J Pathol. 1998 Jan;184(1):58-62 [9582528.001]
  • [Cites] Am J Clin Pathol. 1998 Dec;110(6):782-7 [9844591.001]
  • [Cites] Histopathology. 2004 Dec;45(6):593-602 [15569050.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):161-9 [15467713.001]
  • [Cites] J Mol Diagn. 2005 May;7(2):206-18 [15858144.001]
  • (PMID = 20497539.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fixatives; 1HG84L3525 / Formaldehyde; Oncocytoma, renal
  • [Other-IDs] NLM/ PMC2881070
  •  go-up   go-down


76. Hes O, Michal M, Síma R, Vanecek T, Brunelli M, Martignoni G, Kuroda N, Alvarado Cabrero I, Perez-Montiel D, Hora M, Urge T, Dvorák M, Jarosová M, Yang X: Renal oncocytoma with and without intravascular extension into the branches of renal vein have the same morphological, immunohistochemical, and genetic features. Virchows Arch; 2008 Feb;452(2):193-200
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (3) the absence of metastases suggests an overall benign behavior of this tumor, but this has to be substantiated by further studies with a long-term follow-up; and (4) in a renal tumor with granular cytoplasm showing renal vein extension, it is necessary to carefully exclude renal cell carcinomas such as chromophobe RCC, oncocytic variant of papillary RCC, and granular variant of clear cell RCC.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Kidney Neoplasms / pathology. Renal Veins / pathology

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):871-83 [9255250.001]
  • [Cites] Arch Pathol Lab Med. 2002 May;126(5):610-2 [11958671.001]
  • [Cites] J Pathol. 1997 Oct;183(2):131-3 [9390023.001]
  • [Cites] J Urol. 1988 Mar;139(3):585-7 [3343746.001]
  • [Cites] Br J Urol. 1988 Jul;62(1):89-90 [3408879.001]
  • [Cites] Br J Urol. 1996 Jun;77(6):927-8 [8705242.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):987-9 [9307203.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):161-9 [15467713.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1576-81 [16327429.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):21-40 [9503504.001]
  • [Cites] Am J Surg Pathol. 1999 Jul;23(7):772-80 [10403299.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):281-91 [11859199.001]
  • [Cites] Am J Surg Pathol. 1997 Jan;21(1):1-12 [8990136.001]
  • [Cites] J Urol. 2006 Jun;175(6):2302-6 [16697863.001]
  • [Cites] J Comput Assist Tomogr. 1986 Nov-Dec;10 (6):1054-6 [3537029.001]
  • [Cites] J Urol. 1993 Nov;150(5 Pt 1):1380-3 [8411404.001]
  • [Cites] Adv Anat Pathol. 1999 Jan;6(1):1-11 [10197234.001]
  • [Cites] Ann Diagn Pathol. 2006 Jun;10(3):133-9 [16730306.001]
  • (PMID = 18066590.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


77. Zubakov D, Stupar Z, Kovacs G: Differential expression of a new isoform of DLG2 in renal oncocytoma. BMC Cancer; 2006;6:106
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of a new isoform of DLG2 in renal oncocytoma.
  • BACKGROUND: Renal oncocytoma, a benign tumour of the kidney, may pose a differential diagnostic problem due to overlapping phenotype with chromophobe renal cell carcinoma or other types of renal cell tumours.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / genetics. Guanylate Kinase / genetics. Kidney Neoplasms / diagnosis. Kidney Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2005 Jan;36(1):22-8 [15712178.001]
  • [Cites] Am J Clin Pathol. 1999 Jun;111(6):796-803 [10361516.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jul 15;160(2):120-5 [15993267.001]
  • [Cites] Virchows Arch. 2005 Dec;447(6):938-46 [16133362.001]
  • [Cites] Histopathology. 2000 Sep;37(3):264-8 [10971703.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1639-51 [11337362.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):957-60 [11861363.001]
  • [Cites] Genome Res. 2002 Apr;12(4):656-64 [11932250.001]
  • [Cites] Int J Dev Biol. 2002;46(4):511-8 [12141438.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):925-32 [12598325.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6810-8 [14555994.001]
  • [Cites] Histopathology. 2004 Jun;44(6):542-6 [15186268.001]
  • [Cites] Histopathology. 2004 Nov;45(5):452-9 [15500648.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Histopathology. 1993 Jan;22(1):1-8 [8436337.001]
  • [Cites] Neuron. 1996 Jul;17(1):103-13 [8755482.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):2081-8 [8952540.001]
  • [Cites] J Pathol. 1997 Oct;183(2):131-3 [9390023.001]
  • [Cites] Am J Surg Pathol. 1998 Apr;22(4):419-24 [9537468.001]
  • [Cites] J Pathol. 1998 Jan;184(1):58-62 [9582528.001]
  • [Cites] Hum Pathol. 2005 Mar;36(3):262-8 [15791570.001]
  • (PMID = 16640776.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Protein Isoforms; 0 / Tumor Suppressor Proteins; EC 2.7.4.8 / DLG2 protein, human; EC 2.7.4.8 / Guanylate Kinase
  • [Other-IDs] NLM/ PMC1524971
  •  go-up   go-down


78. Kuehn A, Paner GP, Skinnider BF, Cohen C, Datta MW, Young AN, Srigley JR, Amin MB: Expression analysis of kidney-specific cadherin in a wide spectrum of traditional and newly recognized renal epithelial neoplasms: diagnostic and histogenetic implications. Am J Surg Pathol; 2007 Oct;31(10):1528-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chromophobe renal cell carcinoma and renal oncocytoma are reported to be variably positive for Ksp-cad with some studies suggesting a discriminatory role for Ksp-cad.
  • Reactivity with Ksp-cad was observed in the following tumors: chromophobe renal cell carcinoma [23/25 (92%), diffuse (>50% of tumor cells)] positivity and membranous characteristically accentuating the "plant cell-like" histomorphology of the typical (clear) type, renal oncocytoma [15/20 (75%), usually diffuse staining with predominantly membranous accentuation], papillary renal cell carcinoma [5/17 (29%) all focal to moderate, eosinophilic type or type 2-3/7 (43%), basophilic type or type 1-2/10 (20%)], Xp11 translocation carcinoma [1/4 (25%), diffuse positivity] and clear cell renal cell carcinoma [6/36 (17%) all focal, clear cell renal cell carcinoma with prominent eosinophilic cells 1/7 (14%)].
  • Immunoreactivity was higher when evaluating whole histologic sections than with tissue microarrays for both chromophobe renal cell carcinoma (100% vs. 60%) and renal oncocytoma (100% vs. 55%).
  • The findings argue against the use of Ksp-cad in differentiating chromophobe renal cell carcinoma and renal oncocytomas and further support their relationship to the distal nephron.
  • In the similar diagnostic setting, caution must be exercised, however, in differentiating chromophobe renal cell carcinoma and renal oncocytoma from the eosinophilic variant of papillary renal cell carcinoma as moderate expression of Ksp-cad may be observed in papillary renal cell carcinoma.
  • In conclusion, Ksp-cad is a useful tumor type associated marker for distinguishing chromophobe renal cell carcinoma and renal oncocytoma from the wide range of nonintercalated cell-related adult renal epithelial neoplasms; addition of this marker to a panel comprised of other histologic subtype-associated markers may greatly facilitate histologic subclassification of adult renal epithelial neoplasms.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma, Medullary / metabolism. Carcinoma, Medullary / pathology. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Carcinoma, Transitional Cell / metabolism. Carcinoma, Transitional Cell / pathology. Eosinophilia / metabolism. Eosinophilia / pathology. Humans. Immunoenzyme Techniques. Immunohistochemistry / methods. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17895753.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDH16 protein, human; 0 / Cadherins
  •  go-up   go-down


79. Bach AM, Zhang J: Contemporary radiologic imaging of renal cortical tumors. Urol Clin North Am; 2008 Nov;35(4):593-604; vi
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / radiography. Adenocarcinoma, Clear Cell / ultrasonography. Adenoma, Chromophobe / diagnosis. Adenoma, Chromophobe / radiography. Adenoma, Chromophobe / ultrasonography. Female. Humans. Magnetic Resonance Imaging. Male. Radiographic Image Enhancement. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18992613.001).
  • [ISSN] 0094-0143
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 104
  •  go-up   go-down


80. Rocca PC, Brunelli M, Gobbo S, Eccher A, Bragantini E, Mina MM, Ficarra V, Zattoni F, Zamò A, Pea M, Scarpa A, Chilosi M, Menestrina F, Bonetti F, Eble JN, Martignoni G: Diagnostic utility of S100A1 expression in renal cell neoplasms: an immunohistochemical and quantitative RT-PCR study. Mod Pathol; 2007 Jul;20(7):722-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty-one clear cell, 32 papillary, and 51 chromophobe renal cell carcinomas, and 40 oncocytomas, 164 samples of normal renal parenchyma adjacent to the tumors and 13 fetal kidneys were analyzed.
  • The levels of S100A1 mRNA detected by quantitative RT-PCR analysis of frozen tissues from seven clear cell, five papillary, and six chromophobe renal cell carcinomas, four oncocytomas, and nine samples of normal renal tissues adjacent to neoplasms were compared with the immunohistochemical detection of protein expression.
  • Thirty-seven renal oncocytomas out of 40 (93%) were positive for S100A1, whereas 48 of 51 (94%) chromophobe renal cell carcinomas were negative.
  • Statistical analyses comparing the different expression of S100A1 in clear cell and chromophobe renal cell carcinomas observed by immunohistochemical and RT-PCR methods showed significant values (P<0.001), such as when comparing by both techniques the different levels of S100A1 expression in chromophobe renal cell carcinomas and oncocytomas (P<0.001).
  • Our study shows that S100A1 protein is expressed in oncocytomas, clear cell and papillary renal cell carcinomas but not in chromophobe renal cell carcinomas.
  • Its immunodetection is potentially useful for the differential diagnosis between chromophobe renal cell carcinoma and oncocytoma.
  • [MeSH-minor] Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / metabolism. Diagnosis, Differential. Humans. Immunohistochemistry. Kidney / chemistry. Kidney / metabolism. Kidney / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483815.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / S100 Proteins; 0 / S100A1 protein
  •  go-up   go-down


81. Rebouissou S, Vasiliu V, Thomas C, Bellanné-Chantelot C, Bui H, Chrétien Y, Timsit J, Rosty C, Laurent-Puig P, Chauveau D, Zucman-Rossi J: Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. Hum Mol Genet; 2005 Mar 1;14(5):603-14
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, previous identification of biallelic inactivation of HNF1alpha in hepatocellular adenoma identified its tumor suppressor function in hepatocarcinogenesis.
  • The seminal observation of an ovarian carcinoma in a MODY5 patient who subsequently developed a chromophobe renal cell carcinoma, prompted us to screen for HNF1beta and HNF1alpha inactivation in a series of 20 ovarian and 35 renal neoplasms.
  • Biallelic HNF1beta inactivation was found in two of 12 chromophobe renal carcinomas by association of a germline mutation and a somatic gene deletion.
  • In these cases, the expression of PKHD1 (polycystic kidney and hepatic disease 1) and UMOD (Uromodulin), two genes regulated by HNF1beta, was turned off.
  • In normal and tumor renal tissues, we showed the existence of a network of transcription factors differentially regulated in tumor subtypes.
  • Furthermore, we suggest that HNF1beta functions as a tumor suppressor gene in chromophobe renal cell carcinogenesis through a PKHD1 expression control.

  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15649945.001).
  • [ISSN] 0964-6906
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / HNF1A protein, human; 0 / HNF1B protein, human; 0 / Hepatocyte Nuclear Factor 1-alpha; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 126548-29-6 / Hepatocyte Nuclear Factor 1; 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


82. Huang W, Kanehira K, Drew S, Pier T: Oncocytoma can be differentiated from its renal cell carcinoma mimics by a panel of markers: an automated tissue microarray study. Appl Immunohistochem Mol Morphol; 2009 Jan;17(1):12-7
Genetic Alliance. consumer health - Renal cell carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Differentiating oncocytoma from its renal cell carcinoma (RCC) mimics, particularly chromophobe RCC, can be difficult, especially when limited tissue is available for evaluation.
  • DESIGN: A renal cell neoplasm tissue microarray was constructed including oncocytoma (n=30), chromophobe RCC (n=18), conventional RCC (n=64), papillary RCC (n=50), and benign renal tissues (n=31).
  • RESULT: EABA was positive in 97% of oncocytoma, 26% of conventional RCC and 35% of papillary RCC with granular/eosinophilic (G/E) features and 6% of chromophobe RCC.
  • Vimentin was also negative in chromophobe RCC.
  • CK7 was positive in up to 81% of papillary RCC and 63% of chromophobe RCC, and essentially negative in conventional RCC and oncocytoma.
  • CONCLUSIONS: EABA is an excellent marker for oncocytoma, which can be useful in differentiating oncocytoma from chromophobe RCC.
  • Vimentin can be useful in discriminating chromophobe RCC from papillary or conventional RCCs.

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18769342.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Vimentin; EC 2.7.11.22 / MOK protein, human; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


83. Rowsell C, Fleshner N, Marrano P, Squire J, Evans A: Papillary renal cell carcinoma within a renal oncocytoma: case report of an incidental finding of a tumour within a tumour. J Clin Pathol; 2007 Apr;60(4):426-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary renal cell carcinoma within a renal oncocytoma: case report of an incidental finding of a tumour within a tumour.
  • The most common renal tumours are clear cell, papillary, chromophobe and collecting duct renal cell carcinomas (RCCs), and benign oncocytomas and angiomyolipomas.
  • Tumours with hybrid features between some of these entities have been recognised; in particular, tumours with features of both chromophobe RCC and oncocytoma.
  • The incidental finding of a papillary RCC located in an oncocytoma in a nephrectomy specimen from a 75-year-old man is described.
  • To our knowledge, this is the first report of a papillary RCC being identified within an oncocytoma.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Mixed Tumor, Malignant / pathology


84. Rao Q, Zhou XJ, Shi QL, Yin HL, Ma HH, Zhou HB, Zhang RS: [Expression of Ksp-cadherin in renal epithelial neoplasm and its clinicopathologic significance]. Zhonghua Bing Li Xue Za Zhi; 2007 Jan;36(1):15-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the expression of a novel marker, kidney-specific-protein (Ksp)-cadherin, in renal epithelial neoplasms and its clinicopathologic significance.
  • METHODS: Immunohistochemical study (using EnVision method) for Ksp-cadherin, CD10, vimentin, epithelial membrane antigen and CK7 was carried out in normal human kidney samples, as well as in 166 cases of primary renal neoplasms (including 120 cases of clear cell renal cell carcinoma (RCC), 20 cases of papillary RCC (type I papillary RCC 15 cases and type II papillary RCC 5 cases), 18 cases of chromophobe RCC and 8 cases of oncocytoma).
  • It was also detected in 23% (27/120) of clear cell RCC, 20% (4/20) of papillary RCC, 100% (18/18) of chromophobe RCC and 75% (6/8) of oncocytoma.
  • CD10 was also expressed in chromophobe RCC in cytoplasmic pattern, compared with membranous staining in the other tumors.
  • CK7 expression was mainly seen in chromophobe RCC and papillary RCC, while epithelial membrane antigen was expressed in all variants of RCC.
  • It carries relatively high specificity and sensitivity in diagnosis of chromophobe RCC and oncocytoma.
  • [MeSH-major] Adenoma, Oxyphilic / metabolism. Cadherins / metabolism. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374232.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CDH16 protein, human; 0 / Cadherins; 0 / Vimentin; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


85. Costa VL, Henrique R, Ribeiro FR, Pinto M, Oliveira J, Lobo F, Teixeira MR, Jerónimo C: Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer; 2007;7:133
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A panel of 18 gene promoters was assessed by quantitative methylation-specific PCR (QMSP) in 85 primarily resected renal tumors representing the four major histologic subtypes (52 clear cell (ccRCC), 13 papillary (pRCC), 10 chromophobe (chRCC), and 10 oncocytomas) and 62 paired normal tissue samples.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Adenoma, Oxyphilic / genetics. Biomarkers, Tumor / metabolism. Carcinoma, Papillary / genetics. Carcinoma, Renal Cell / genetics. Kidney Neoplasms / diagnosis. Kidney Neoplasms / genetics. Neoplasm Proteins / metabolism

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 1994 Aug 11;22(15):2990-7 [8065911.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):655-63 [7180965.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8472-8 [15623627.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4037-43 [15930338.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4097-106 [15930345.001]
  • [Cites] World J Urol. 2005 Jul;23(3):202-12 [15812574.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6582-8 [16166436.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] J Urol. 2006 Jun;175(6):2302-6 [16697863.001]
  • [Cites] Urology. 2006 May;67(5):873-80 [16698345.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5021-8 [16707423.001]
  • [Cites] Nucleic Acids Res. 2000 Apr 15;28(8):E32 [10734209.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] J Natl Cancer Inst. 2001 Nov 21;93(22):1747-52 [11717336.001]
  • [Cites] Am J Pathol. 2002 Feb;160(2):605-12 [11839581.001]
  • [Cites] Urology. 2002 Dec;60(6):941-6 [12475646.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1370-5 [12684406.001]
  • [Cites] Methods Mol Biol. 2003;226:33-4 [12958476.001]
  • [Cites] J Natl Cancer Inst. 2003 Nov 5;95(21):1634-7 [14600096.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7641-5 [14633683.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8695-9 [14695183.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1975-86 [15026333.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):381-93 [15122209.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3972-9 [15217927.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4010-4 [15217932.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5511-7 [15289362.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):805-10 [15375503.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7276-83 [15534102.001]
  • (PMID = 17645803.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDH1 protein, human; 0 / Cadherins; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  • [Other-IDs] NLM/ PMC1940017
  •  go-up   go-down


86. Shomori K, Nagashima Y, Kuroda N, Honjo A, Tsukamoto Y, Tokuyasu N, Maeta N, Matsuura K, Hijiya N, Yano S, Yokoyama S, Ito H, Moriyama M: ARPP protein is selectively expressed in renal oncocytoma, but rarely in renal cell carcinomas. Mod Pathol; 2007 Feb;20(2):199-207
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interestingly, ARPP was not detected in any of 11 chromophobe RCCs, suggesting that ARPP may be useful for differential diagnosis between oncocytoma and chromophobe RCC.
  • [MeSH-major] Adenoma, Oxyphilic / metabolism. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism. Muscle Proteins / metabolism. Nuclear Proteins / metabolism. Repressor Proteins / metabolism

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17206105.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ANKRD2 protein, human; 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Muscle Proteins; 0 / Nuclear Proteins; 0 / Repressor Proteins
  •  go-up   go-down


87. Lechpammer M, Resnick MB, Sabo E, Yakirevich E, Greaves WO, Sciandra KT, Tavares R, Noble LC, DeLellis RA, Wang LJ: The diagnostic and prognostic utility of claudin expression in renal cell neoplasms. Mod Pathol; 2008 Nov;21(11):1320-9
GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tissue microarrays were created from paraffin-embedded tissue samples from 141 patients with renal cell carcinomas or oncocytoma (90 clear cell, 22 papillary, 17 chromophobe renal cell carcinomas, and 12 oncocytomas).
  • Moderate to strong claudin 7 expression was significantly more common in chromophobe renal cell carcinomas (94%) than in oncocytomas (55%; P=0.041).
  • Only negative to weak claudin 8 staining was detected in all chromophobe renal cell carcinomas, whereas there were no claudin 8 negative oncocytomas and 8% exhibited a weak staining pattern (P<0.0001).
  • Due to their distinctive expression patterns, claudins 7 and 8 can be used as useful immunohistochemical markers for the separation of chromophobe renal cell carcinomas from oncocytomas, whereas claudins 3 and 4 may serve as indicators of prognosis in clear cell renal cell carcinomas.
  • [MeSH-major] Adenoma, Oxyphilic / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism. Membrane Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Mod Pathol. 2009 Feb;22(2):321
  • (PMID = 18587324.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN1 protein, human; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / CLDN7 protein, human; 0 / Claudin-1; 0 / Claudin-3; 0 / Claudin-4; 0 / Claudins; 0 / Membrane Proteins; 0 / claudin 8
  •  go-up   go-down


88. Bárcena C, Martínez MA, Ortega MP, Muñoz HG, Sárraga GU: Mitochondria with tubulovesicular cristae in renal oncocytomas. Ultrastruct Pathol; 2010 Dec;34(6):315-20
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renal oncocytoma and chromophobe renal cell carcinoma (CRCC) are closely related tumors.
  • They are considered the extremes of a spectrum with several variants.
  • [MeSH-minor] Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / ultrastructure. Biomarkers, Tumor / metabolism. Carcinoma, Renal Cell / diagnosis. Diagnosis, Differential. Female. Humans. Incidental Findings. Male. Microscopy, Electron, Transmission. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21070162.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; Oncocytoma, renal
  •  go-up   go-down


89. Brennan C, Srigley JR, Whelan C, Cooper J, Delahunt B: Type 2 and clear cell papillary renal cell carcinoma, and tubulocystic carcinoma: a unifying concept. Anticancer Res; 2010 Feb;30(2):641-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical and pathological features of multiple different renal neoplasms arising in a setting of end-stage renal disease in a 72-year-old male are described.
  • The kidney showed features of renal oncocytosis with multiple oncocytomas, hybrid tumours and chromophobe renal carcinoma.
  • The occurrence of these three tumours in a setting of end-stage kidney disease is unique and suggests a common pathogenesis.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Kidney Tubules / pathology. Neoplasms, Multiple Primary / pathology


90. Sibony M, Vieillefond A: [Non clear cell renal cell carcinoma. 2008 update in renal tumor pathology]. Ann Pathol; 2008 Oct;28(5):381-401
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The group of oncocytomas/chromophobe renal cell carcinomas can be considered as a spectrum from benign (oncocytoma) to malignant neoplasm (chromophobe renal cell carcinoma).
  • [MeSH-minor] Adenoma, Oxyphilic / classification. Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / pathology. Carcinoma / classification. Carcinoma / genetics. Carcinoma / pathology. Chromosome Mapping. Chromosomes, Human. Humans. Immunohistochemistry. Kidney / pathology. Kidney Tubules, Collecting / pathology. Necrosis

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068393.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 84
  •  go-up   go-down


91. Gökden N, Greene GF, Bayer-Garner IB, Spencer HJ, Sanderson RD, Gökden M: Expression of CD138 (Syndecan-1) in renal cell carcinoma is reduced with increasing nuclear grade. Appl Immunohistochem Mol Morphol; 2006 Jun;14(2):173-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Formalin-fixed, paraffin-embedded tissue sections of 50 renal cell carcinomas (RCCs) (40 clear-cell RCCs of various nuclear grades, 10 of which harbored metastases; 6 papillary RCCs, 4 chromophobe RCCs) and 4 oncocytomas were stained immunohistochemically for CD138 using the monoclonal antibody B-B4 (CD138).
  • Immunoreactivity was membranous in all clear-cell RCCs, chromophobe RCCs, and oncocytomas and was located at the basal aspect of cytoplasm in papillary RCCs.

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785785.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SDC1 protein, human; 0 / Syndecan-1
  •  go-up   go-down


92. Bakshi N, Kunju LP, Giordano T, Shah RB: Expression of renal cell carcinoma antigen (RCC) in renal epithelial and nonrenal tumors: diagnostic Implications. Appl Immunohistochem Mol Morphol; 2007 Sep;15(3):310-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three tissue microarrays containing 241 REN samples, 192 samples of a wide variety of neoplasms and 170 adrenal tumor samples, respectively, were stained with RCC monoclonal antibody.
  • Out of 241 REN, 173 were positive for RCC (sensitivity 72%): clear cell 72%, papillary 95%, chromophobe 91%, unclassified 85%, oncocytoma 75%, sarcomatoid 20%, and metastatic RCC 40%.
  • RCC expression was seen equally among adrenal adenoma and carcinoma group.

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721277.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; EC 2.7.11.22 / MOK protein, human; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


93. Algaba F: Renal adenomas: pathological differential diagnosis with malignant tumors. Adv Urol; 2008;:974848

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal adenomas: pathological differential diagnosis with malignant tumors.
  • The renal adenomas can be confused by imaging diagnosis with malignant renal tumors, but there are also real biological dilemmas to determine their behavior.
  • The consensus decisions are the following. (1) The adenoma of clear cells is not accepted, instead it is considered that all the clear-cell tumors are carcinomas, with greater or lesser aggressiveness. (2) Among the papillary neoplasms the WHO 2004 renal cell tumors classification are considered as papillary adenomas tumors with a maximum diameter of 5 mm and may represent a continuum biological process to papillary renal cell carcinoma.
  • The papillary adenomas associated with End-kidney and/or acquired cystic disease may have a different pathogenesis. (3) To consider a tumor as an oncocytoma the size is not important, only the cytological features, microscopic, ultrastructural, and immunohistochemically can help, but some chromosomal observations introduce some questions about its relation with the chromophobe renal cell carcinoma. (4) Finally, the metanephric adenoma, a tumor with some morphological similarity with the nephroblastoma must be considered in the renal adenomas diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endourol. 2007 Aug;21(8):819-23 [17867935.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):489-500 [17414095.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):239-46 [17056094.001]
  • [Cites] Urology. 2006 Oct;68(4):737-40 [17070344.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):218-24 [16424894.001]
  • [Cites] Am J Clin Pathol. 2006 Feb;125(2):217-22 [16393684.001]
  • [Cites] BJU Int. 2005 Dec;96(9):1275-9 [16287444.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jul 1;152(1):23-8 [15193438.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):101-4 [11172302.001]
  • (PMID = 18846240.001).
  • [ISSN] 1687-6369
  • [Journal-full-title] Advances in urology
  • [ISO-abbreviation] Adv Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2563151
  •  go-up   go-down


94. Genega EM, Ghebremichael M, Najarian R, Fu Y, Wang Y, Argani P, Grisanzio C, Signoretti S: Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol; 2010 Dec;134(6):873-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated its immunohistochemical expression in 317 primary and 42 metastatic renal neoplasms (186 clear cell, 52 papillary, 35 chromophobe, 47 unclassified, and 15 Xp11.2 translocation renal cell carcinomas [RCCs]; 26 oncocytomas; 2 metanephric adenomas; 1 urothelial carcinoma; 1 mixed epithelial and stromal tumor; and 1 angiomyolipoma); 7 neoplasms were unknown as to whether they were primary or metastatic.
  • One chromophobe carcinoma had focal expression.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2001 Mar;158(3):905-19 [11238039.001]
  • [Cites] Med Oncol. 2009;26 Suppl 1:18-22 [19165638.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):802-11 [12576453.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):750-61 [12766578.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):2-7 [12838292.001]
  • [Cites] World J Gastroenterol. 2003 Jul;9(7):1398-403 [12854129.001]
  • [Cites] Urol Clin North Am. 2003 Nov;30(4):843-52 [14680319.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6290S-5S [15448019.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):655-63 [7180965.001]
  • [Cites] Int J Cancer. 1986 Oct 15;38(4):489-94 [2428759.001]
  • [Cites] JAMA. 1995 Feb 15;273(7):564-70 [7837390.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2827-31 [9230182.001]
  • [Cites] J Urol. 1999 Feb;161(2):381-6; discussion 386-7 [9915408.001]
  • [Cites] Curr Oncol Rep. 2005 Mar;7(2):109-15 [15717944.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):640-6 [15832088.001]
  • [Cites] Clin Lab Med. 2005 Jun;25(2):247-57 [15848735.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3714-21 [15897568.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):51-68 [16512599.001]
  • [Cites] Semin Oncol. 2006 Oct;33(5):534-43 [17045082.001]
  • [Cites] Histopathology. 2006 Dec;49(6):594-602 [17163844.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):225-9 [17210525.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4757-64 [17947723.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Am J Surg Pathol. 2009 Feb;33(2):241-7 [18941400.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):281-91 [11859199.001]
  • (PMID = 21088149.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA101942; United States / NCI NIH HHS / CA / P50CA101942
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ NIHMS511251; NLM/ PMC3778911
  •  go-up   go-down


95. Rogers CG, Singh A, Blatt AM, Linehan WM, Pinto PA: Robotic partial nephrectomy for complex renal tumors: surgical technique. Eur Urol; 2008 Mar;53(3):514-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathology confirmed clear-cell renal cell carcinoma (n=3), hybrid oncocytic tumor (n=2), chromophobe renal cell carcinoma (n=2), and oncocytoma (n=1).
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / surgery. Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / surgery. Adult. Aged. Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / surgery. Equipment Design. Female. Follow-Up Studies. Humans. Length of Stay. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed. Video Recording

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endourol. 2005 May;19(4):441-5; discussion 445 [15910252.001]
  • [Cites] Urology. 2005 Jun;65(6):1086-9 [15913733.001]
  • [Cites] Urology. 2005 Jul;66(1):45-9 [15992879.001]
  • [Cites] World J Urol. 2006 Jun;24(2):171-9 [16544167.001]
  • [Cites] Eur Urol. 2007 Jan;51(1):186-91; discussion 191-2 [16822607.001]
  • [Cites] J Urol. 2007 Jan;177(1):70-4; discussion 74 [17162003.001]
  • [Cites] BJU Int. 2005 Feb;95(3):377-83 [15679798.001]
  • [Cites] Urology. 2004 Nov;64(5):914-8 [15533477.001]
  • [Cites] J Urol. 1991 Aug;146(2):278-82 [1830346.001]
  • [Cites] Am J Surg. 2004 Oct;188(4A Suppl):45S-51S [15476651.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1264-6 [15371820.001]
  • [Cites] J Urol. 2004 Sep;172(3):871-3 [15310986.001]
  • [Cites] J Urol. 2005 Sep;174(3):850-3; discussion 853-4 [16093968.001]
  • [Cites] J Urol. 2006 Jul;176(1):36-9 [16753361.001]
  • [CommentIn] Eur Urol. 2008 Mar;53(3):521-2 [17961911.001]
  • [CommentIn] Eur Urol. 2008 Mar;53(3):522-3 [17961908.001]
  • (PMID = 17961910.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 SC006659-25
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ NIHMS65236; NLM/ PMC2644902
  •  go-up   go-down


96. Skinnider BF, Folpe AL, Hennigar RA, Lim SD, Cohen C, Tamboli P, Young A, de Peralta-Venturina M, Amin MB: Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol; 2005 Jun;29(6):747-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors.
  • Individual cases can show overlapping morphologic features, necessitating the use of ancillary methods.
  • RENs (including clear cell [conventional] renal cell carcinoma (RCC), papillary RCC, chromophobe RCC, renal oncocytoma, collecting duct carcinoma (CDC), renal medullary carcinoma (RMC), urothelial carcinoma, metanephric adenoma (MA), tubulocystic carcinoma (TC) (also known as low-grade collecting duct carcinoma), and mucinous tubular and spindle cell carcinoma) were immunostained for CK subtypes (CK5/CK6, 7, 8, 13, 14, 17, 18, 19, 20), high molecular weight CKs 1, 5, 10, 14 (HMWCK), and vimentin (Vim).
  • Chromophobe RCCs were typically CK7+, CK8+, CK18+, and Vim-, and could be distinguished from oncocytomas (typically CK7-).

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2006 Oct;30(10):1337 [17001169.001]
  • (PMID = 15897741.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


97. Kauffman EC, Barocas DA, Chen YT, Yang XJ, Scherr DS, Tu JJ: Differential expression of KAI1 metastasis suppressor protein in renal cell tumor histological subtypes. J Urol; 2009 May;181(5):2305-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This problem is most notable for the chromophobe subtype of renal cell carcinoma, which can be histologically indistinguishable from oncocytoma with investigational molecular markers failing to provide reliable differentiation.
  • MATERIALS AND METHODS: Immunohistochemical staining for KAI1 protein was performed in 152 nephrectomy specimens, including 48 clear cell, 35 papillary and 31 chromophobe renal cell carcinoma samples, 28 oncocytomas and 10 tumor-free kidneys.
  • KAI1 mRNA levels were compared by quantitative reverse transcriptase-polymerase chain reaction in an additional 22 chromophobe renal cell carcinoma and oncocytoma samples.
  • In contrast, 27 of 31 chromophobe renal cell carcinoma specimens (87%) expressed KAI1 protein, most at moderate or high levels.
  • The diagnostic accuracy of KAI1 immunostaining for discerning chromophobe renal cell carcinoma from oncocytoma was 90% with similar results observed at the RNA level.
  • CONCLUSIONS: KAI1 is an accurate biomarker for chromophobe renal cell carcinoma that may aid in the diagnostic differentiation of chromophobe renal cell carcinoma from oncocytoma.
  • It remains to be determined whether KAI1 expression contributes to the low metastatic potential of chromophobe renal cell carcinoma.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / pathology. Extracellular Matrix Proteins / metabolism. Kidney Neoplasms / genetics. Kidney Neoplasms / pathology. Nerve Tissue Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19303095.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins; 0 / KAL1 protein, human; 0 / Nerve Tissue Proteins
  •  go-up   go-down


98. Abrahams NA, Tamboli P: Oncocytic renal neoplasms: diagnostic considerations. Clin Lab Med; 2005 Jun;25(2):317-39, vi
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article discusses the features of renal oncocytoma (including oncocytosis), chromophobe renal cell carcinoma (RCC), and clear cell RCC; explores the relationship between renal oncocytoma and chromophobe RCC; briefly discusses other tumors with abundant eosinophilic cytoplasm; and emphasizes the differential diagnosis of such tumors.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15848739.001).
  • [ISSN] 0272-2712
  • [Journal-full-title] Clinics in laboratory medicine
  • [ISO-abbreviation] Clin. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FLCN protein, human; 0 / Proteins; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins
  • [Number-of-references] 98
  •  go-up   go-down


99. Surgit O: Clipless and sutureless laparoscopic adrenalectomy carried out with the LigaSure device in 32 patients. Surg Laparosc Endosc Percutan Tech; 2010 Apr;20(2):109-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In another patient, a renal cell carcinoma in the left kidney had metastasized to the right adrenal gland.
  • Both the kidney and the contralateral adrenal gland were removed laparoscopically during the same operation.
  • Adrenal tumor types included adrenocortical adenoma (16 patients), pheochromocytoma (13 patients), malignant pheochromocytoma (1 patient), chromophobic carcinoma (1 patient), and metastasis from a renal cell carcinoma (1 patient).
  • For patients with conditions such as renal cell carcinoma combined with metastasis to the contralateral adrenal gland, nephrectomy, and contralateral adrenalectomy can be carried out during the same laparoscopic operation.
  • [MeSH-minor] Adenoma, Chromophobe / surgery. Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / surgery. Adrenocortical Adenoma / surgery. Adult. Aged. Blood Loss, Surgical. Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Female. Humans. Kidney Neoplasms / surgery. Male. Middle Aged. Nephrectomy / methods. Pheochromocytoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20393338.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Deshpande A, Munshi M: Renal oncocytoma with hyaline globules: cytologic diagnosis by guided fine needle aspiration, a case report. Indian J Pathol Microbiol; 2005 Apr;48(2):230-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renal oncocytoma has to be distinguished from granular renal cell carcinoma (RCC) and chromophobe cell carcinoma, because of the markedly different prognosis.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / pathology. Kidney Neoplasms / diagnosis. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16758678.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down






Advertisement